Novel non-fluorinated quinolone compounds and uses thereof

Novel non-fluorinated quinolone compounds targeting DNA gyrase and TLR-MD2 in Propionibacterium acnes provide a dual-action treatment for acne, addressing drug resistance and inflammation.

JP2024541618AActive Publication Date: 2024-11-08GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024532450
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-21
Filing Date
2022-11-30
Publication Date
2024-11-08
Estimated Expiration
2042-11-30

AI Technical Summary

Technical Problem

There is a need for new antibiotics to treat acne caused by Propionibacterium acnes, as existing antibiotics like erythromycin and clindamycin face increasing drug resistance, and quinolones have shown potential anti-Propionibacterium acnes and anti-inflammatory activity.

Method used

Development of novel non-fluorinated quinolone compounds that target DNA gyrase and TLR-MD2, providing a dual-action approach to treat acne by synthesizing compounds represented by formula (II) and their pharmaceutically acceptable salts.

Benefits of technology

The novel quinolone compounds effectively treat acne by targeting Propionibacterium acnes and reducing drug resistance, while also exhibiting anti-inflammatory properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541618000001_ABST
    Figure 2024541618000001_ABST
Patent Text Reader

Abstract

The present invention relates to novel non-fluorinated quinolone compounds and their uses, and more particularly to compounds of formula (II) and pharma- ceutically acceptable salts thereof: JPEG2024541618000079.jpg34170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to CN202111444560.2 filed on November 30, 2021 and CN202210864782.8 filed on July 21, 2022.

[0002] The present invention relates to novel non-fluorinated quinolone compounds and uses thereof, particularly to compounds represented by formula (II) and pharma- ceutically acceptable salts thereof: [Background technology]

[0003] Quinolone drugs appeared in the 1960s, and after decades of development, they have been constantly updated and improved, and are widely used in clinical practice.Quinolone drugs have the characteristics of wide antibacterial spectrum, strong antibacterial activity, easy administration, no cross-resistance with other commonly used antibacterial drugs, and so on, so they have been rapidly popularized in clinical practice, and have become one of the important commonly used drugs in the world at present.With the further modification and research of this type of drug, it has been found that this type of drug also has many other biological activities, such as antitumor, antivirus and anti-inflammation, which have been reported.

[0004] Acne is a skin disease that affects more than 85% of humans. It usually occurs on the face, neck, and upper trunk. Although acne development is multifactorial, a cutaneous commensal bacterium, Propionibacterium acnes, plays a major role in the formation of acne lesions. It is a type of infection of the sebaceous and oil glands of the skin. By activating Toll-like receptor 2 (TLR2) on innate immune cells, Propionibacterium acnes can trigger various cytokines (e.g., IL-6, IL-8, and IL-12) and stimulate the expression of chemokines that recruit other host immune cells.

[0005] Among antibiotics for treating acne, erythromycin and clindamycin are the most widely applied, but due to their long-term widespread use, drug resistance has become increasingly serious, and there is an urgent need for new antibiotics that can be used to treat acne. In recent years, many patents and papers have reported that quinolone drugs have good anti-Propionibacterium acnes activity and anti-inflammatory activity. Therefore, the research of a new generation of quinolone drugs for treating acne is of great theoretical and economic value. Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention provides a compound, stereoisomer or pharma- ceutically acceptable salt thereof of formula (II): JPEG2024541618000002.jpg44170T1 is N, NH, CR1, and N + R1(A - ), T2 is selected from N and CR2; A - is F - , Cl - , Br - , I - , O.H. - , and HCO3 - is selected from X is selected from -C(R7R8)- and -C(R7R8)-C(R7R8)-; Y is selected from -O-, -S-, -NH-, and -C(R7R8)-; Z is selected from -C(R7R8)-; or -YZ- is selected from -C(R9)=C(R9)-; R1 is selected from H, F, Cl, Br, I, -OH, -NH2, -CN, and -CH3; R2 is H, F, Cl, Br, I, -OH, -NH2, -CN, and C 1~3 alkyl, wherein said C 1~3 The alkyl group may optionally be one, two or three R a is replaced by R3 is H, F, Cl, Br, I, =O, -OH, -NH2, -CN, -NHC(=NH)NH2, C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 alkoxy, wherein said C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 Alkoxy is optionally, independently, one, two or three R b or R1 and R3 together with the atom to which they are connected form a 5- to 6-membered heterocycloalkyl, a 5- to 6-membered heterocyclenyl, or a 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heterocycloalkyl, the 5- to 6-membered heterocyclenyl, and the 5- to 6-membered heteroaryl are each independently optionally selected from 1, 2, 3, or 4 R c is replaced by R4 is H, C 1~3 Alkyl, C 3~6 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, 1~3 Alkyl, C 3~6 Cycloalkyl, phenyl, and 5- to 6-membered heteroaryl each independently optionally have 1, 2, 3, or 4 R d is replaced by R5 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R6 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; each R7, R8, and R9 is independently selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; Each R a are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; Each R b are each independently F, Cl, Br, I, -OH, -NH2, -CN, C 1~3 Alkoxy, C 3~6 cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and phenyl, wherein1~3 Alkoxy, C 3~6 cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and phenyl are each independently optionally substituted by 1, 2, 3, or 4 R; Each R c are each independently selected from F, Cl, Br, I, -OH, -NH2, -CN, and -CH3; Each R d are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; Each R is independently F, Cl, Br, I, -OH, -NH2, -NO2, -CN, -ONHC(=NH)NH2, and C 1~3 alkyl, The "hetero" in the 5- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heterocyclenyl, and 5- to 6-membered heteroaryl each independently represents 1, 2, 3, or 4 heteroatoms or heteroatom groups selected from O, NH, S, and N.

[0007] The present invention provides a compound, stereoisomer or pharma- ceutically acceptable salt thereof of formula (II): JPEG2024541618000003.jpg55170T1 is selected from N and CR1, T2 is selected from N and CR2; X is selected from -C(R7R8)- and -C(R7R8)-C(R7R8)-; Y is selected from -O-, -S-, -NH-, and -C(R7R8)-; Z is selected from -C(R7R8)-; or -YZ- is selected from -C(R9)=C(R9)-; R1 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R2 is H, F, Cl, Br, I, -OH, -NH2, -CN, and C 1~3 alkyl, wherein said C 1~3 The alkyl group may optionally be one, two or three R a is replaced by R3 is H, F, Cl, Br, I, =O, -OH, -NH2, -CN, C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 alkoxy, wherein said C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 Alkoxy is optionally, independently, one, two or three R b or R1 and R3 together with the carbon atom to which they are attached form a 5-6 membered heterocycloalkyl, a 5-6 membered heterocyclenyl, and a 5-6 membered heteroaryl, wherein the 5-6 membered heterocycloalkyl, the 5-6 membered heterocyclenyl, and the 5-6 membered heteroaryl are each independently optionally selected from 1, 2, 3, or 4 R c is replaced by R4 is H, C 1~3 Alkyl, C 3~6 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, 1~3 Alkyl, C 3~6 Cycloalkyl, phenyl, and 5- to 6-membered heteroaryl each independently optionally have 1, 2, 3, or 4 R d is replaced by R5 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R6 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; each R7, R8, and R9 is independently selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R a are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; R b are each independently F, Cl, Br, I, -OH, -NH2, -CN, C 3~6 cycloalkyl, 3- to 6-membered heterocycloalkyl, and phenyl, wherein 3~6cycloalkyl, 3- to 6-membered heterocycloalkyl, and phenyl are each independently optionally substituted with 1, 2, 3, or 4 R; R c are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; R d are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; each R is independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; The "hetero" in the 5- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heterocyclenyl, and 5- to 6-membered heteroaryl each independently represents 1, 2, 3, or 4 heteroatoms or heteroatom groups selected from -O-, -NH-, -S-, and -N-.

[0008] The present invention provides a compound of formula (I), a stereoisomer, or a pharma- ceutically acceptable salt thereof. JPEG2024541618000004.jpg35170 (However, T1 is selected from N and CR1; T2 is selected from N and CR2; X is selected from -C(R7R8)- and -C(R7R8)-C(R7R8)-; Y is selected from -O- and -C(R7R8)-; Z is selected from -C(R7R8)-; or -YZ- is selected from -C(R9)=C(R9)-; R1 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R2 is H, F, Cl, Br, I, -OH, -NH2, -CN, and C 1~3 alkyl, wherein said C 1~3 The alkyl group may optionally be one, two or three R a is replaced by R3 is H, F, Cl, Br, I, -OH, -NH2, -CN, C 1~3 Alkylamino, and C 1~3alkoxy, wherein said C 1~3 Alkylamino, and C 1~3 Alkoxy is optionally, independently, one, two or three R b or R1 and R3 together with the carbon atom to which they are attached form a 5- to 6-membered heterocycloalkyl, a 5- to 6-membered heterocyclenyl, and a 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heterocyclenyl, and the 5- to 6-membered heteroaryl are each independently optionally selected from 1, 2, 3, or 4 R c is replaced by R4 is H, C 1~3 Alkyl, C 3~6 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, 1~3 Alkyl, C 3~6 Cycloalkyl, phenyl, and 5- to 6-membered heteroaryl each independently optionally have 1, 2, 3, or 4 R d is replaced by R5 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R6 is selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; each R7, R8, and R9 is independently selected from H, F, Cl, Br, I, -OH, -NH2, and -CN; R a are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; R b are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; R c are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; R d are each independently selected from F, Cl, Br, I, -OH, -NH2, and -CN; The "hetero" in the 5- to 6-membered heterocycloalkyl, 5- to 6-membered heterocyclenyl, and 5- to 6-membered heteroaryl each independently represents 1, 2, 3, or 4 heteroatoms or heteroatom groups selected from -O-, -NH-, -S-, and -N-.

[0009] JPEG2024541618000005.jpg11170

[0010] In some embodiments of the invention, T1 is selected from N, with the other variables being as defined herein.

[0011] In some embodiments of the invention, T1 is selected from CH, with the other variables being as defined herein.

[0012] In some embodiments of the invention, T1 is selected from NH, with the other variables being as defined herein.

[0013] In some embodiments of the invention, T1 is N + R1(A - ) and other variables are as defined herein.

[0014] In some embodiments of the invention, T1 is N + R1(Cl - ) and other variables are as defined herein.

[0015] In some embodiments of the invention, T2 above is selected from N, with the other variables being as defined herein.

[0016] In some embodiments of the invention, T2 is selected from CH, with the other variables being as defined herein.

[0017] In some embodiments of the present invention, - is F - , Cl - , Br - , and I -and the other variables are as defined herein.

[0018] In some embodiments of the present invention, - is Cl - and the other variables are as defined herein.

[0019] In some embodiments of the present invention, X is selected from -CH2-, and other variables are as defined herein.

[0020] In some embodiments of the present invention, Y is selected from -O-, with the other variables being as defined herein.

[0021] In some embodiments of the present invention, Y is selected from -CH2-, and other variables are as defined herein.

[0022] In some embodiments of the present invention, Z is selected from -CH2-, and other variables are as defined herein.

[0023] In some embodiments of the present invention, -YZ- above is selected from -CH=CH-, and other variables are as defined herein.

[0024] In some embodiments of the invention, each R is independently selected from -NO2, -ONHC(=NH)NH2, and -CH3, and all other variables are as defined herein.

[0025] In some embodiments of the invention, each R b are each independently selected from F, Cl, Br, -OH, -NH2, -OCH2CH3, cyclobutyl, oxetanyl, oxolanyl, azetidinyl, 5-membered heteroaryl, and phenyl, wherein said -OCH2CH3, cyclobutyl, oxetanyl, oxolanyl, azetidinyl, 5-membered heteroaryl, and phenyl are each independently optionally substituted with 1, 2, 3, or 4 R, and R and the other variables are as defined herein.

[0026] In some embodiments of the invention, each R b are each independently selected from F, Cl, Br, -OH, -NH2, cyclobutyl, oxetanyl, azetidinyl, and phenyl, wherein said cyclobutyl, oxetanyl, azetidinyl, and phenyl are each independently optionally substituted with 1, 2, 3, or 4 R, and R and the other variables are as defined herein.

[0027] In some embodiments of the invention, each R b are each independently selected from F, Cl, Br, -OH, -NH2, -OCH2CH3, cyclobutyl, oxetanyl, 1,3-dioxane, azetidinyl, imidazolyl, and phenyl, wherein said -OCH2CH3, cyclobutyl, oxetanyl, 1,3-dioxane, azetidinyl, imidazolyl, and phenyl are each independently optionally substituted with 1, 2, 3, or 4 R, and R and the other variables are as defined herein.

[0028] JPEG2024541618000006.jpg41170

[0029] JPEG2024541618000007.jpg38170

[0030] JPEG2024541618000008.jpg31170

[0031] JPEG2024541618000009.jpg22170

[0032] In some embodiments of the invention, each R b are each independently selected from F, Cl, Br, and -OH, and other variables are as defined herein.

[0033] In some embodiments of the invention, each R c are each independently selected from -CH3, and the other variables are as defined herein.

[0034] In some embodiments of the invention, each R d are each independently selected from F, Cl, Br, and -NH2, and other variables are as defined herein.

[0035] In some embodiments of the invention, each R d are each independently selected from F and -NH2, and the other variables are as defined herein.

[0036] In some embodiments of the present invention, R1 above is selected from H, with the other variables being as defined herein.

[0037] In some embodiments of the present invention, R2 above is selected from H and -CH3, and other variables are as defined herein.

[0038] In some embodiments of the present invention, R2 above is selected from H, with the other variables being as defined herein.

[0039] In some aspects of the invention, R3 is selected from H, F, Cl, Br, =O, -OH, -NH2, -CN, -NHC(=NH)NH2, -CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -NHCH2CH2CH3, -N(CH3)CH2CH3, and -OCH3, wherein -NHC(=NH)NH2, -CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -NHCH2CH2CH3, -N(CH3)CH2CH3, and -OCH3 are each independently optionally selected from 1, 2, or 3 R b is replaced by R b and other variables are as defined in the present invention.

[0040] In some forms of the invention, R3 is selected from H, F, Cl, Br, =O, -OH, -NH2, -CN, -CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -NHCH2CH2CH3, and -OCH3, where -CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -NHCH2CH2CH3, and -OCH3 are each independently optionally selected from 1, 2, or 3 R b is replaced by R b and other variables are as defined in the present invention.

[0041] In some forms of the invention, R3 is selected from H, F, Cl, Br, -OH, -NH2, -CN, -NHCH3, -N(CH3)2, -NCH2CH3, and -OCH3, where NHCH3, -N(CH3)2, -NCH2CH3, and -OCH3 are each independently optionally selected from 1, 2, or 3 R b is replaced by R b and other variables are as defined in the present invention.

[0042] JPEG2024541618000010.jpg65170

[0043] JPEG2024541618000011.jpg41170

[0044] In some embodiments of the invention, R3 is selected from -NH2, -NHCH3, -N(CH3)2, -NCH2CH3, -NCH2CH2OH, and -OCH3, with the other variables being as defined herein.

[0045] In some embodiments of the invention, R4 is C 3~6 cycloalkyl, wherein said C 3~6 Cycloalkyl optionally has 1, 2, 3 or 4 R d and other variables are as defined herein.

[0046] In some aspects of the invention, R4 is selected from H, -CH2CH3, cyclopropyl, phenyl, and pyridyl, wherein said -CH2CH3, cyclopropyl, phenyl, and pyridyl are each independently optionally selected from 1, 2, 3, or 4 R d and other variables are as defined herein.

[0047] JPEG2024541618000012.jpg56170

[0048] JPEG2024541618000013.jpg17170

[0049] In some embodiments of the present invention, R5 and R6 are each independently selected from H and F, and other variables are as defined herein.

[0050] In some embodiments of the present invention, R6 above is selected from H and F, and the other variables are as defined herein.

[0051] In some embodiments of the present invention, R5 and R6 are each independently selected from H, and other variables are as defined herein.

[0052] In some embodiments of the present invention, each of R7, R8, and R9 is independently selected from H, and all other variables are as defined herein.

[0053] JPEG2024541618000014.jpg34170

[0054] JPEG2024541618000015.jpg31170

[0055] JPEG2024541618000016.jpg34170

[0056] JPEG2024541618000017.jpg31170

[0057] JPEG2024541618000018.jpg45170

[0058] JPEG2024541618000019.jpg30170

[0059] JPEG2024541618000020.jpg31170

[0060] JPEG2024541618000021.jpg20170

[0061] JPEG2024541618000022.jpg50170

[0062] JPEG2024541618000023.jpg45170

[0063] In some aspects of the invention, the compounds have the structures shown in formulas (II-3), (II-4), (II-5), and (II-6). JPEG2024541618000024.jpg67170 (where T1, T2 and R3 are as defined in the present invention.)

[0064] In some embodiments of the invention, the compound has a structure according to formula (II-3A), (II-3B), (II-3C), (II-3D), (II-3E), (II-5A), and (II-6A). JPEG2024541618000025.jpg96170 (However, A - , R1, R2 and R3 are as defined in the present invention.

[0065] The present invention also includes any combination of the above variables.

[0066] The present invention also provides a compound, stereoisomer or pharma- ceutically acceptable salt thereof represented by the formula: JPEG2024541618000026.jpg217170JPEG2024541618000027.jpg144170

[0067] The present invention also provides a compound, stereoisomer or pharma- ceutically acceptable salt thereof represented by the formula: JPEG2024541618000028.jpg87170

[0068] The present invention also provides the use of the above compounds, stereoisomers or pharma- ceutically acceptable salts thereof in the manufacture of antibacterial and anti-inflammatory medicaments.

[0069] In some forms of the invention, the use is preferably in the manufacture of a medicament for treating acne.

[0070] The present invention also provides the use of the above compound, stereoisomer or pharma- ceutically acceptable salt thereof in the manufacture of a medicament for treating acne.

[0071] The present invention also provides a method for biological testing of the above compounds.

[0072] Experimental method 1: Experiment on induction of inflammation model in THP-1 cells by Propionibacterium acnes Purpose of the experiment Establishing a Propionibacterium acnes-induced THP-1 cell inflammation model. Experimental Consumables Strain: Propionibacterium acnes ATCC 6919; Medium: brucella agar (containing 5% LHB + 5μg / ml Hemin + 1μg / ml Vitamin K1); Cells: THP-1 ATCC TIB-202; Medium: RPMI1640 (gibco 22400-089) + 10% heat inactivated FBS + 1x GlutaMAX (100x GlutaMAX: gibco 3050-061). Experimental Program a) Production of inflammatory stimuli i. Propionibacterium acnes ATCC 6919 glycerin tube was inoculated into brucella agar (containing 5% LHB + 5 μg / mL Hemin + 1 μg / mL Vitamin K1) and incubated anaerobically at 37 °C for 48 h. II. The plate culture was harvested and suspended in PBS, and the bacterial count was then increased to 3×10 9 Adjust to cfu / mL. Then inactivate in a water bath at 80°C for 30 minutes. CFU counts should be performed before and after bacterial inactivation. iii. The inactivated bacterial suspension is individually packaged and stored in a refrigerator at 80°C until use. b) Preparation of THP-1 cells i. Resuscitation and culture of cells: THP-1 cells cryopreserved in liquid nitrogen are resuscitated in RPMI1640 (containing 10% FBS and 1× glutamax). After one passage, they are ready for use in experiments. ii. Cell inoculation: 2×10 5 cells (190 μL, 1.1 × 10 6 cfu / mL) were inoculated into 96-well flat-bottom plates and stored until use. c) Induction of cells i. 8 μL of heat-inactivated Propionibacterium acnes (concentration: 3 × 10 9 cfu / mL (high concentration), 6×10 8 The cells were stimulated with 1000 cfu / mL (low concentration) of IgG4 (tested) to induce inflammatory cytokines, and two parallel plates were prepared. After 1 h of induction, the test plates were set at 37°C and cultured for 24 h, 48 h, and 72 h. PBS was also used as a negative control. After incubation, the test plates were centrifuged (4000 RPM, 5 min) and the supernatant was collected. The plates were stored at -80°C until use. d) Enzyme-linked immunosorbent assay i. Detect the cytokine IL-8 levels in the cell supernatant according to the instructions of the Human CXCL8 / IL-8 Quantikine ELISA Kit (R&D-D8000C). ii. Detect the cytokine IL-6 level in the cell supernatant according to the instructions of Human IL-6 Quantikine ELISA Kit (R&D-D6050).

[0073] Technical effects In the present invention, a compound represented by formula (I) and a pharma- ceutically acceptable salt thereof are synthesized by a simple manufacturing method, and a novel non-fluorinated quinolone antibiotic is provided, which is a new drug that acts on the dual targets of DNA gyrase and TLR-MD2, treats acne caused by Propionibacterium acnes, and solves the problem of drug resistance of Propionibacterium acnes. Definitions and Explanations

[0074] Unless otherwise specified, the following terms and phrases as used herein are intended to have the following meanings: Certain terms and phrases should not be regarded as indefinite or uncertain, but should be understood in their general sense, unless specifically defined. When trade names are used herein, they are intended to refer to the corresponding commercial product or its active ingredients.

[0075] As used herein, the term "pharmacologically acceptable" means those compounds, materials, compositions and / or dosage forms which are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human beings and animals without undue toxicity, irritation, anaphylaxis, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0076] The term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention made from a compound found in the present invention having a specific substituent and a relatively harmless acid or base. When a compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting such a compound with a sufficient amount of base in a pure solution or in a suitable inert solvent. When a compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting such a compound with a sufficient amount of acid in a pure solution or in a suitable inert solvent. Certain compounds of the present invention contain basic and acidic functional groups and can therefore be converted into either base or acid addition salts. The present invention also contemplates any N-cation quaternary ammonium salt formed from a compound having a N group. + R1(A -) indicates that the heteroatom N is a positive ion, a quaternary ammonium salt, where A is F - , Cl - , Br - , I - , O.H. - , HCO3 - , HSO3 - , HSO4 - , NO3 - , ClO - ,BrO - , I3 - , ClO3 - , ClO4 - , H.C.O.O. - , CH3COO - , H2PO4 - And so on.

[0077] The pharma- ceutically acceptable salts of the present invention can be synthesized from parent compounds that contain an acid or base group by conventional chemical methods. Generally, methods for preparing such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometrically appropriate base or acid in water or an organic solvent, or in a mixture of both.

[0078] In addition to the salt forms, the compounds according to the present invention also have prodrug forms. The prodrugs of the compounds described herein are easily chemically changed under physiological conditions and converted to the compounds of the present invention. Furthermore, the prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in the in vivo environment.

[0079] Some compounds of the present invention can exist in unsolvated or solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are included within the scope of the present invention.

[0080] Unless otherwise specified, the term "treatment" is intended to mean any process that may slow, halt, inhibit, or prevent the progression of a disease, but does not necessarily mean that all symptoms are eliminated.

[0081] The compounds of the present invention may have specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Substituents such as alkyl may also have additional asymmetric carbon atoms. All of these isomers and mixtures thereof are included within the scope of the present invention.

[0082] Unless otherwise specified, the terms "enantiomers" or "optical isomers" refer to stereoisomers that are mirror images of one another.

[0083] Unless otherwise specified, the terms "cis-trans isomers" or "geometric isomers" refer to the inability to freely rotate about a double bond or a single bond of a ring-forming carbon atom.

[0084] Unless otherwise indicated, the term "diastereomer" means a stereoisomer whose molecules have two or more centers of chirality and which are not in a mirror-image relationship between the molecules.

[0085] Unless otherwise specified, "(+)" denotes dextrorotatory, "(-)" denotes levorotatory, and "(±)" denotes racemic.

[0086] JPEG2024541618000029.jpg22170

[0087] The compounds of the present invention may exist in specific. Unless otherwise specified, the term "tautomer" or "tautomeric form" means that at room temperature, different functional group isomers are in dynamic equilibrium and rapidly convert into each other. When tautomers are possible (such as in solution), chemical equilibrium of tautomers can be achieved. For example, prototropic tautomers (also called prototropic tautomers) include interconversions by proton transfer, such as ketone-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions involving rearrangement of some bond electrons. A specific example of ketone-enol tautomerization is the interconversion between the tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one.

[0088] Unless otherwise specified, the terms "enriched in one isomer," "isomer-enriched," "enriched in one enantiomer," or "enantiomer-enriched" mean less than 100% of one of these isomers or enantiomers, and more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9% of that isomer or enantiomer.

[0089] Unless otherwise specified, the term "isomer excess" or "enantiomeric excess" refers to the relative percentage difference between two isomers or two enantiomers. For example, if one isomer or enantiomer is present at 90% and the other isomer or enantiomer is present at 10%, then the isomer or enantiomer excess (ee value) is 80%.

[0090] Optically active (R)- and (S)-isomers, as well as D- and L-isomers, can be prepared by chiral synthesis or chiral reagents, or other conventional techniques. To obtain one enantiomer of the compound of the present invention, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary is cleaved to provide the pure desired enantiomer. In addition, when the molecule contains a basic (e.g., amino) or acidic (e.g., carboxyl) functional group, the diastereomeric salt is formed with an appropriate optically active acid or base, and the diastereomers are separated by conventional methods and then recovered to obtain the pure enantiomers. Furthermore, separation of enantiomers and diastereomers is generally achieved by using chromatography using chiral stationary phases, optionally combined with chemical derivatization methods (e.g., formation of carbamates from amines).

[0091] The compounds of the present invention may contain unnatural ratios of atomic isotopes at one or more of the atoms that constitute such compounds. For example, tritium ( 3 H), iodine-125( 125 I) or C-14( 14 The compounds may be labeled with radioisotopes such as C). For example, deuterium may be substituted for hydrogen to form deuterated drugs, where the bond between deuterium and carbon is more robust than the bond between normal hydrogen and carbon, and compared to non-deuterated drugs, deuterated drugs have the advantages of reduced toxicity and side effects, improved drug stability, enhanced therapeutic efficacy, and longer biological half-life. All isotopic variants of the compounds of the present invention, whether radioactive or not, are within the scope of the present invention.

[0092] "Optional" or "optionally" means that the subsequently described event or condition may, but does not necessarily, occur, and the description includes cases where the event or condition occurs and cases where it does not occur.

[0093] JPEG2024541618000030.jpg48170

[0094] The term "optionally substituted" means that, unless otherwise specified, the group may be substituted or unsubstituted, and the types and numbers of substituents may be any as long as they are chemically achievable.

[0095] When any variable (e.g., R) occurs more than one time in a composition or structure of a compound, each definition is independent. Thus, for example, if a group is substituted with 0-2 R, said group may also be optionally substituted with up to 2 R, with each occurrence of R having an independent option. Further, combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0096] When the number of linking groups is 0, for example, -(CRR)0- indicates that this linking group is a single bond.

[0097] When one variable is selected from a single bond, it indicates that the two groups connected thereby are directly linked, e.g., when L represents a single bond in ALZ, it indicates that the structure is substantially AZ.

[0098] The absence of a substituent indicates that the substituent is not present; for example, the absence of X in AX indicates that the structure is essentially A.

[0099] If there is no indication as to which atom a recited substituent is linked to the substituent, then the substituent may be attached by any atom; for example, pyridyl may be linked as a substituent through any carbon atom on the pyridine ring.

[0100] JPEG2024541618000031.jpg167170

[0101] Unless otherwise stated, the term "alkyl," by itself or as part of another substituent, refers to a linear or branched saturated hydrocarbon radical. 1~6 Alkyl or C 1~3 It may be an alkyl, which is optionally substituted with one or more of the following groups: oxo, hydroxy, amino, nitro, halogen, cyano, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0102] Unless otherwise specified, "C 1~3 The term "alkyl" refers to a linear or branched saturated hydrocarbon group having 1 to 3 carbon atoms. 1~3 is C 1~2 and C 2~3 alkyl, which may be monovalent (e.g., methyl), divalent (e.g., methylene), or polyvalent (e.g., methine). 1~3 Examples of alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl, isopropyl), and the like.

[0103] Unless otherwise specified, the term "alkoxy" refers to an alkyl group linked to the remainder of the molecule through an oxygen atom. 1~6 Alkoxy or C 1~3 It may be an alkoxy, which is optionally substituted with one or more of oxo, hydroxy, amino, nitro, halogen, cyano, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0104] Unless otherwise specified, "C 1~3 The term "alkoxy" refers to an alkyl group having 1 to 3 carbon atoms linked to the remainder of the molecule through an oxygen atom. 1~3 Alkoxy is C 1~2 , C 2~3 , C3 and C2 alkoxy, etc. 1~3 Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy, isopropoxy), and the like.

[0105] Unless otherwise specified, "C 1~3 The term "alkylamino" refers to an alkyl group having 1 to 3 carbon atoms linked to the remainder of the molecule through an amino. 1~3 Alkylamino is C 1~2 , C3 and C2 alkylamino, etc. 1~3 Examples of alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, and the like.

[0106] The terms "halo" or "halogen," by themselves or as part of another substituent, represent, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0107] The term "cycloalkyl" refers to a carbocycle that is fully saturated and can exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise specified, the carbocycle typically has 3 to 12 members. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, and the like. Said cycloalkyl is C 3~6It may be a cycloalkyl, which is optionally substituted with one or more of the following groups: oxo, hydroxy, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C(O)NH2, -C(O)NH-alkyl, -C(O)N(alkyl)2, -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)2NH2, -S(O)2NH-alkyl, -S(O)2N(alkyl)2, cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0108] Unless otherwise specified, "C 3~6 "Cycloalkyl" refers to a saturated cyclic hydrocarbon group having 3 to 6 carbon atoms, which is a monocyclic or bicyclic ring system. 3~6 Cycloalkyl is C 3~5 , C 4~5 and C 5~6 cycloalkyl, which may be monovalent, divalent, or polyvalent. 3~6 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0109] The term "heterocyclyl" refers to a non-aromatic ring that can be fully saturated or partially unsaturated (but not fully unsaturated heteroaromatic) and can exist as a monocyclic, bridged, or spirocyclic ring. The heterocycle is generally a 3-12 membered ring containing 1-3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen, unless otherwise indicated. Non-limiting examples of heterocyclyl include, but are not limited to, oxylyl, tetrahydrofuranyl, dihydrofuranyl, pyrrolidinyl, N-methylpyrrolidinyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyrazolidinyl, 4H-pyranyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, and the like. The heterocyclyl is optionally substituted by one or more of the following groups: oxo, hydroxy, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C(O)NH, -C(O)NH-alkyl, -C(O)N(alkyl), -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)-alkyl, -S(O)NH, -S(O)NH-alkyl, -S(O)N(alkyl), cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0110] The term "heterocycloalkyl" refers to a cyclic group that is fully saturated and can exist as a monocyclic, bridged, or spirocyclic ring. The heterocycle is generally a 4- to 12-membered ring containing 1-3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, and / or nitrogen, unless otherwise indicated. Non-limiting examples of 4-membered heterocycloalkyls include, but are not limited to, azetidinyl, oxetanyl, and thibutanyl. Examples of 5-membered heterocycloalkyls include, but are not limited to, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, isoxazolidinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl, and tetrahydropyrazolyl. Examples of 6-membered heterocycloalkyl include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl, 1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,3-dithianyl, and 1,4-dithianyl. Examples of 7-membered heterocycloalkyl include, but are not limited to, azepanyl, oxeptanyl, and thiepanyl. The heterocycloalkyl may be a 4-6 membered heterocycloalkyl, or a monocyclic heterocycloalkyl having 5 or 6 ring atoms. The heterocycloalkyl is optionally substituted with one or more of oxo, hydroxy, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C(O)NH, -C(O)NH-alkyl, -C(O)N(alkyl), -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)-alkyl, -S(O)NH, -S(O)NH-alkyl, -S(O)N(alkyl), cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0111] Unless otherwise specified, the term "3 to 6 membered heterocycloalkyl", by itself or in combination with other terms, refers to a saturated cyclic group of 3 to 6 ring atoms, each of which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur heteroatoms may be optionally oxidized (i.e., C(O), NO, and S(O)). p (p is 1 or 2). Monocyclic and bicyclic rings are included, and bicyclic rings include spiro, fused, and bridged rings. Furthermore, for this "3- to 6-membered heterocycloalkyl", a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule. The 3- to 6-membered heterocycloalkyl includes 4- to 6-membered, 5- to 6-membered, 4-membered, 5-membered, and 6-membered heterocycloalkyl. Examples of 3- to 6-membered heterocycloalkyl include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidyl, 2-piperidyl, and 3-piperidyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, or hexahydropyridazinyl, etc.

[0112] Unless otherwise specified, the term "5- to 6-membered heterocycloalkyl", by itself or in combination with other terms, refers to a saturated cyclic group consisting of 5 to 6 ring atoms, each of which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur atoms may be optionally oxidized (i.e., C(O), NO, and S(O)). p(p is 1 or 2). Monocyclic and bicyclic ring systems are included, where bicyclic ring systems include spiro rings, fused rings, and bridged rings. Additionally, for this "5- to 6-membered heterocycloalkyl", a heteroatom may occupy the position of attachment of the heterocycloalkyl to the remainder of the molecule. The 5- to 6-membered heterocycloalkyl includes 5-membered heterocycloalkyl and 6-membered heterocycloalkyl. Examples of 5-6 membered heterocycloalkyl include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl, and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, etc.

[0113] Unless otherwise specified, the term "5- to 6-membered heterocycloalkenyl," by itself or in combination with other terms, refers to a partially unsaturated cyclic group consisting of 5 to 6 ring atoms, each containing at least one carbon-carbon double bond, in which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S and N, and the remainder are carbon atoms, in which the nitrogen atom is optionally quaternized, and the carbon, nitrogen and sulfur atoms may be optionally oxidized (i.e., C(O), NO and S(O)). p (wherein p is 1 or 2). This includes monocyclic and bicyclic ring systems, where bicyclic systems include spiro, fused and bridged rings, and all rings in the system are non-aromatic. Furthermore, for this "5- to 6-membered heterocycloalkenyl", a heteroatom may occupy the position of attachment of the heterocycloalkenyl to the remainder of the molecule. The 5- to 6-membered heterocycloalkenyl includes 5-membered heterocycloalkenyl, 6-membered heterocycloalkenyl, etc. JPEG2024541618000032.jpg33170

[0114] The term "heteroaryl" refers to a monocyclic or fused polycyclic ring system containing at least one ring atom selected from N, O, S, with the remaining ring atoms being C, and having at least one aromatic ring. Preferred heteroaryls have a single 4-8 membered ring, especially 5-8 membered ring, or multiple fused rings containing 6-14, especially 6-10 ring atoms. Non-limiting examples of heteroaryls include, but are not limited to, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl, triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl, and the like. The heteroaryl may be a 5-6 membered heteroaryl. The heteroaryl is optionally substituted with one or more of the following groups: hydroxy, amino, nitro, halogen, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkoxy, alkylamino, dialkylamino, haloalkylamino, halodialkylamino, carboxyl, -C(O)O-alkyl, -OC(O)-alkyl, -C(O)NH, -C(O)NH-alkyl, -C(O)N(alkyl), -NHC(O)-alkyl, -C(O)-alkyl, -S(O)-alkyl, -S(O)-alkyl, -S(O)NH, -S(O)NH-alkyl, -S(O)N(alkyl), cycloalkyl, cycloalkyloxy, heterocyclyl, heterocyclooxy, heterocycloalkyl, heterocycloalkyloxy, heteroaryl, heteroaryloxy, aryl, or aryloxy.

[0115] Unless otherwise specified, the terms "5- to 6-membered heteroaromatic ring" and "5- to 6-membered heteroaryl" of the present invention can be used interchangeably, and the term "5- to 6-membered heteroaryl" refers to a monocyclic group consisting of 5 to 6 ring atoms and having a conjugated π-electron system, in which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur atoms may be optionally oxidized (i.e., C(O), NO, and S(O)).p , p is 1 or 2). The 5- to 6-membered heteroaryl may be linked to the remainder of the molecule via a heteroatom or a carbon atom. The 5- to 6-membered heteroaryl includes 5- and 6-membered heteroaryl. Examples of the 5- to 6-membered heteroaryl include pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl, and 5-oxazolyl, etc.), triazolyl (including 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, and 4H-1,2,4-triazolyl, etc.). triazolyl, tetrazolyl, isoxazolyl (such as 3-isoxazolyl, 4-isoxazolyl, and 5-isoxazolyl), thiazolyl (such as 2-thiazolyl, 4-thiazolyl, and 5-thiazolyl), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl, and 4-pyridyl, etc.), pyrazinyl, or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.).

[0116] Unless otherwise specified, as used herein, the terms "5-membered heteroaromatic ring" and "5-membered heteroaromatic ring" may be used interchangeably, and the term "5-membered heteroaryl" refers to a monocyclic group consisting of 5 ring atoms and having a conjugated π-electron system, in which 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen, and sulfur atoms may be optionally oxidized (i.e., C(O), NO, and S(O)). p, p is 1 or 2). The 5-membered heteroaryl may be linked to the remainder of the molecule via a heteroatom or a carbon atom. Examples of the 5-membered heteroaryl include pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl, and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl, and 5-oxazolyl, etc.), triazolyl (including 1H-1,2,3-triazolyl, 2 ... -triazolyl, 1H-1,2,4-triazolyl, and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (such as 3-isoxazolyl, 4-isoxazolyl, and 5-isoxazolyl), thiazolyl (such as 2-thiazolyl, 4-thiazolyl, and 5-thiazolyl), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.).

[0117] Unless otherwise specified, C n~n+m Or C n ~C n+m contains any one of n to n+m carbons, e.g., C 1~12 are C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , and C 12 Also includes any of the ranges of n to n+m, for example, C 1~12 is C 1~3 , C 1~6 , C 1~9 , C 3~6 , C 3~9 , C 3~12 , C 6~9 , C 6~12 , and C 9~12Similarly, n-membered to n+m-membered means that the number of atoms on the ring is n to n+m, and for example, a 3- to 12-membered ring includes a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, a 7-membered ring, an 8-membered ring, a 9-membered ring, a 10-membered ring, an 11-membered ring, and a 12-membered ring, and also includes any of the ranges of n to n+m, and for example, a 3- to 12-membered ring includes a 3- to 6-membered ring, a 3- to 9-membered ring, a 5- to 6-membered ring, a 5- to 7-membered ring, a 6- to 7-membered ring, a 6- to 8-membered ring, and a 6- to 10-membered ring, etc.

[0118] The term "leaving group" refers to a functional group or atom that can be replaced by another functional group or atom by a substitution reaction (e.g., a nucleophilic substitution reaction). For example, representative leaving groups include triflates; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate, and the like; acyloxy groups such as acetoxy, trifluoroacetoxy, and the like.

[0119] The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group", or "mercapto protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (such as acetyl, trichloroacetyl, or trifluoroacetyl); alkoxycarbonyl, such as tert-butoxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-bis-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS), 2-(trimethylsilyl)ethoxymethyl (SEM), and tert-butyldimethylsilyl (TBS). The term "hydroxy protecting group" refers to a protecting group suitable for preventing side reactions at hydroxy. Representative hydroxy protecting groups include, but are not limited to, alkyl, such as methyl, ethyl, tert-butyl, etc.; acyl, such as alkanoyl (acetyl, etc.); arylmethyl, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), diphenylmethyl (diphenylmethyl, DPM), etc.; silyl, such as trimethylsilyl (TMS), tert-butyldimethylsilyl (TBS), etc.

[0120] The compounds of the present invention can be prepared by a variety of synthetic methods familiar to those skilled in the art, including the specific embodiments listed below, embodiments formed in combination with other chemical synthetic methods, and equivalent alternatives familiar to those skilled in the art, and preferred embodiments include, but are not limited to, those of the present invention.

[0121] The structure of the compound of the present invention can be confirmed by conventional methods well known to those skilled in the art, and when the present invention relates to the absolute configuration of the compound, the absolute configuration can be verified by conventional means of those skilled in the art. For example, in single crystal X-ray diffraction (SXRD), the cultivated single crystal is collected by Bruker D8 venture diffractometer to collect diffraction intensity data, the light source is CuKα radiation, the scanning method is φ / ω scanning, and after collecting relevant data, the crystal structure is further analyzed by direct method (Shelxs97), so that the absolute configuration can be verified.

[0122] The solvents used in the present invention are commercially available.

[0123] The present invention employs the following abbreviations: DMAP stands for 4-dimethylaminopyridine; DMSO stands for dimethylsulfoxide; CFU stands for colony forming units; DCM stands for dichloromethane; DMF stands for N,N-dimethylformamide; DME stands for ethylene glycol dimethyl ether; TFA stands for trifluoroacetic acid; Boc2O stands for di-t-butyl dicarbonate; NaOH stands for sodium hydroxide; NaH stands for sodium hydride; NBS stands for N-bromosuccinimide; TBSCl stands for tert-butyldimethylchlorosilane; HPLC stands for high pressure liquid chromatography; LCMS stands for liquid chromatography mass spectrometry; SBE-β-CD stands for sulfobutyl ether β-cyclodextrin; PBS stands for phosphate buffered saline.

[0124] Compounds are named according to conventional naming principles in the art or using ChemDraw® software; commercially available compounds are named from the supplier catalog. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0125] The present invention will be described in detail below by examples, but does not mean to limit the present invention. The compounds of the present invention can be prepared by various synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed in combination with other chemical synthesis methods, and equivalent alternative forms well known to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present invention. It is obvious to those skilled in the art that various changes and improvements can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.

[0126] JPEG2024541618000033.jpg165170 Step 1: Preparation of Compound 1-2 Compound 1-1 (5.00 g, 23.14 mmol) was dissolved in thionyl chloride (65.13 g, 547.43 mmol, 39.71 mL). The mixture was stirred at reflux for 2 h. Thionyl chloride was removed by concentration under reduced pressure, then methanol (50 mL) was added, and the mixture was stirred at 65° C. for 1 h. Methanol was removed by concentration under reduced pressure, then aqueous sodium carbonate (50 mL) was added to quench the reaction mixture. Extraction was performed with ethyl acetate (50 mL×2), and the separated organic layer was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1-2. LCMS (ESI) m / z: 229.9 / 231.9 (M+1). Step 2: Preparation of Compounds 1-3 Compound 1-2 (15 g, 65.20 mmol), cyclopropyl borate (11.20 g, 130.4 mmol), copper acetate (23.68 g, 130.4 mmol), 2,2'-bipyridine (20.37 g, 130.4 mmol) and sodium carbonate (20.73 g, 195.60 mmol) were mixed in dichloromethane (240 mL) and replaced with O2 three times, and then the mixture was stirred at 15 to 25 ° C in an oxygen atmosphere for 12 h. The reaction mixture was filtered, water (200 mL) was added to the filtrate, and it was extracted with dichloromethane (100 mL × 2). The separated organic layer was washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 10 / 1) to obtain compound 1-3. LCMS (ESI) m / z: 270.0 / 272.0 (M+1). Step 3: Preparation of Compounds 1-4 Compound 1-3 (1.8 g, 6.66 mmol), diphenylphosphine ferrocene palladium dichloride (487.59 mg, 666.37 μmol), bis(pinacolato)diboron (2.03 g, 8.00 mmol) and potassium acetate (1.96 g, 19.99 mmol) were mixed in dioxane (30 mL) and purged with N2 three times, and then the mixture was stirred at 100 °C under nitrogen atmosphere for 4 h. Water (20 mL) was added to quench the reaction mixture, and it was extracted with ethyl acetate (20 mL × 3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 1-4. LCMS (ESI) m / z: 318.2 (M+1). Step 4: Preparation of Compounds 1-6 Compound 1-5 (6.00 g, 25.97 mmol) was dissolved in dichloromethane (120 mL), and (Boc)2O (14.17 g, 64.92 mmol) and DMAP (317.26 mg, 2.60 mmol) were added. The mixture was then stirred at 15-25°C for 2 hours. The reaction solution was washed with saturated aqueous sodium bicarbonate solution (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1-6. LCMS (ESI) m / z: 431.0 / 433.0 (M+1). Step 5: Preparation of Compounds 1-7 Potassium carbonate (9.61 g, 69.56 mmol) was added to a solution of compound 1-6 (10.00 g, 23.19 mmol) in methanol (45 mL). The mixture was stirred at 15-25 °C for 2 hours. Methanol was removed by concentration under reduced pressure, and then water (50 mL) was added to quench the reaction mixture. Extraction was performed with ethyl acetate (50 mL x 2), and the separated organic layer was washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 0-2 / 1) to obtain compound 1-7. 1 H NMR (400 MHz, CDCl3) δ = 8.02 - 7.95 (m, 1H) 7.93 - 7.86 (m, 1H) 7.41 (br s, 1H) , 3.97 (s, 3H) , 1.51 (s, 9H). Step 6: Preparation of Compounds 1-8 Compound 1-7 (5.70 g, 17.21 mmol) was dissolved in acetone (85 mL), and methyl iodide (2.93 g, 20.65 mmol) and cesium carbonate (16.85 g, 51.64 mmol) were added. The mixture was then stirred at 15-25 °C for 3 h. Water (50 mL) was added to quench the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL x 2). The separated organic layer was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1-8. LCMS (ESI) m / z: 344.9 / 446.9 (M+1). Step 7: Preparation of Compounds 1-9 Compound 1-8 (1.8 g, 5.21 mmol), compound 1-4 (2.1 g, 6.62 mmol), sodium carbonate (1.11 g, 10.43 mmol), diphenylphosphine ferrocene palladium dichloride (381.55 mg, 521.45 μmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (214.07 mg, 521.45 μmol) and palladium acetate (58.54 mg, 260.73 μmol) were mixed in tetrahydrofuran (30 mL) and water (6 mL), and the mixture was substituted with N2 three times, and then the mixture was stirred at 60-65 °C in a nitrogen atmosphere for 10 h. Water (50 mL) was added to quench the reaction mixture, and it was extracted with ethyl acetate (30 mL × 3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=20 / 1 to 5 / 1) to give compound 1-9. LCMS (ESI) m / z: 456.1 (M+1). Step 8: Preparation of Compounds 1-10 Compound 1-9 (0.50 g, 1.10 mmol) was dissolved in tetrahydrofuran (20 mL) at 0° C., and lithium aluminum tetrahydride (166.63 mg, 4.39 mmol) was added. The mixture was then stirred at 0° C. for 2 h. The reaction mixture was quenched by adding water (1 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 1-10. LCMS (ESI) m / z: 300.2 (M+1). Step 9: Preparation of Compounds 1-11 Compound 1-10 (0.30 g, 1.00 mmol) was dissolved in water (10 mL) and concentrated sulfuric acid (18.4 g, 183.85 mmol) was added. The mixture was then stirred at 60° C. for 12 hours. The reaction mixture was quenched by adding saturated aqueous sodium carbonate solution (100 mL) and extracted with ethyl acetate (30 mL×3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 1-11. LCMS (ESI) m / z: 282.1 (M+1). Step 10: Preparation of Compounds 1-12 Compound 1-11 (0.26 g, 924.11 μmol) and diethyl 2-(ethoxymethylene)malonate (0.20 g, 924.11 μmol) were dissolved in toluene (5 mL) and purged with nitrogen three times. The mixture was stirred at 110° C. for 10 hours. The reaction mixture was concentrated under reduced pressure to give compound 1-12. LCMS (ESI) m / z: 452.1 (M+1). Step 11: Preparation of Compounds 1-13 Compound 1-12 (0.12 g, 265.77 μmol) was dissolved in polyphosphoric acid (1.00 g). The mixture was then stirred at 90° C. for 2 h. Water (100 mL) was added to quench the reaction mixture, and the pH was adjusted to 8-9 with potassium carbonate, followed by extraction with dichloromethane (20 mL×4). The separated organic layer was washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 1-13. LCMS (ESI) m / z: 406.1 (M+1). Step 12: Preparation of the hydrochloride salt of compound 1 Compound 1-13 (0.05 g, 123.32 μmol) was dissolved in tetrahydrofuran (1 mL), ethanol (1 mL) and water (0.5 mL), and sodium hydroxide (14.80 mg, 369.96 μmol) was added. The mixture was then stirred at 15-25°C for 2 hours. The reaction mixture was adjusted to pH=5-6 with 1M hydrochloric acid, filtered and concentrated under reduced pressure to obtain a residue. The hydrochloride salt of compound 1 was obtained by purification using preparative HPLC (column: YMC Triart 30×150 mm×7 μm; mobile phase: 0.05% aqueous hydrochloric acid and acetonitrile; gradient: acetonitrile 12%-32%). 1 H NMR (400 MHz, CD3OD) δ = 9.08 (s, 1H), 8.64 (d, J = 8.4 Hz, 1H), 8.39 - 8.28 (m, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.26 (d, J = 9.4 Hz, 1H), 4.89 - 4.88 (m, 4H), 4.51 - 4.39 (m, 1H),3.18 (s, 3H), 1.50 - 1.44 (m, 2H), 1.09 - 1.03 (m, 2H). LCMS (ESI) m / z: 378.1 (M+1).

[0127] JPEG2024541618000034.jpg134170 Step 1: Preparation of compound 2-2 Compound 2-1 (1.00 g, 4.33 mmol) was dissolved in dichloromethane (20 mL), Boc2O (2.36 g, 10.82 mmol) and DMAP (52.88 mg, 432.81 μmol) were added, and the mixture was stirred at 20-25° C. for 2 hours. The reaction solution was washed with saturated sodium bicarbonate (50 mL) and saturated saline (50 mL) in that order, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 2-2. LCMS (ESI) m / z: 374.9 (M-56+1). Step 2: Preparation of compound 2-3 Potassium carbonate (1.44 g, 10.43 mmol) was added to a solution of compound 2-2 (1.50 g, 3.48 mmol) in methanol (20 mL). The mixture was stirred at 20-25° C. for 2 hours. The crude product was stirred in a mixed solvent (petroleum ether / ethyl acetate=1 / 1) and filtered to obtain compound 2-3. 1 H NMR (400 MHz, CDCl3) δ = 8.47 (s, 1H), 8.33 (s, 1H), 7.68 (br s, 1H), 3.98 (s, 3H), 1.56 (s, 9H). LCMS (ESI) m / z: 275.0 (M-56+1). Step 3: Preparation of Compound 2-4 To a solution of compound 2-3 (5.3 g, 16.00 mmol) in acetone (80 mL), cesium carbonate (15.64 g, 48.01 mmol) and methyl iodide (2.73 g, 19.21 mmol) were added. The mixture was stirred at 20-25°C for 3 hours. The crude product was obtained by filtration and concentration under reduced pressure. Compound 2-4 was obtained by silica gel column chromatography (petroleum ether / ethyl acetate = 300 / 1 to 100 / 1). LCMS (ESI) m / z: 289.0 (M-56+1). Step 4: Preparation of Compound 2-5 Compound 1-4 (91.89 mg, 289.70 μmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (23.79 mg, 57.94 μmol), sodium carbonate (61.41 mg, 579.39 μmol), and palladium acetate (6.50 mg, 28.97 μmol) were added to a solution of compound 2-4 (0.1 g, 289.70 μmol) in tetrahydrofuran (2 mL) and water (0.4 mL), and the mixture was purged with nitrogen three times. The mixture was heated to 70° C. and stirred for 22 hours. The mixture was filtered and concentrated under reduced pressure to obtain a crude compound. Compound 2-5 was obtained by thin layer chromatography (petroleum ether / ethyl acetate=5 / 1). LCMS (ESI) m / z: 456.1 (M+1). Step 5: Preparation of Compounds 2-6 Lithium aluminum tetrahydrogen (316.63 mg, 8.34 mmol) was added to a solution of compound 2-5 (950 mg, 2.09 mmol) in tetrahydrofuran (20 mL) at 0° C., and the mixture was stirred at 0-10° C. for 2 h. The reaction was quenched with water (0.33 mL), 15% sodium hydroxide (0.33 mL), and water (1 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 2-6. LCMS (ESI) m / z: 344.2 (M-56+1). Step 6: Preparation of Compounds 2-7 Compound 2-6 (500 mg, 1.67 mmol) was dissolved in 50% aqueous sulfuric acid (10 mL), heated to 60° C., and stirred for 12 hours. The reaction solution was diluted with water (10 mL), adjusted to pH=9 with sodium carbonate, and extracted with ethyl acetate (20 mL). Compound 2-7 was obtained by purification using thin layer chromatography (petroleum ether / ethyl acetate=1 / 1). LCMS (ESI) m / z: 282.2 (M+1). Step 7: Preparation of Compounds 2-8 Compound 2-7 (90.00 mg, 319.88 μmol) and diethyl 2-(ethoxymethylene)malonate (83.00 mg, 383.86 μmol) were dissolved in toluene (5 mL) at 25° C., and the mixture was heated to 110° C. and stirred for 14 hours. Compound 2-8 was obtained by concentration. LCMS (ESI) m / z: 452.3 (M+1). Step 8: Preparation of the trifluoroacetate salt of compound 2-9 Compound 2-8 (0.15 g, 332.22 μmol) was dissolved in polyphosphoric acid (88.59 μmol) solution, heated to 90° C., and stirred for 2 hours. After filtration, the filtrate was purified by preparative HPLC (column: Shim-pack C18 150*25 mm*10 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 12% to 42%) to obtain the trifluoroacetate salt of compound 2-9. LCMS (ESI) m / z: 406.3 (M+1). Step 9: Preparation of the trifluoroacetate salt of compound 2 Sodium hydroxide (2.96 mg, 73.99 μmol) was added to a solution of trifluoroacetate salt of compound 2-9 (6 mg, 14.80 μmol) in methanol (0.3 mL) and water (0.1 mL) at 25° C. The mixture was stirred at 25° C. for 2 hours, filtered, and the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 12% to 42%) to obtain the trifluoroacetate salt of compound 2. 1 H NMR (400 MHz, CD3OD+D2O) δ = 9.15 (s, 1H), 8.59 (d, J = 8.4 Hz, 1H), 8.31 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 3.37 (s, 1H), 3.32 (s, 4H), 3.14 (s, 3H), 2.72 (s, 1H), 2.09 (s, 2H), 1.58 - 1.44 (m, 2H), 1.06 (br d, J = 2.3 Hz, 2H). LCMS (ESI) m / z:378.2 (M+1).

[0128] JPEG2024541618000035.jpg100170 Step 1: Preparation of compound 3-2 Compound 3-1 (5.00 g, 23.69 mmol) was dissolved in t-butyl alcohol (60 mL) and water (60 mL), and potassium permanganate (18.72 g, 118.45 mmol) was added. The mixture was then stirred at 80° C. for 6 hours. The reaction solution was cooled to room temperature, filtered, washed with water (20 mL) and methyl t-butyl ether (50 mL), respectively, and the aqueous phase was separated, adjusted to pH=4 with 1M hydrochloric acid, and concentrated under reduced pressure to obtain compound 3-2. LCMS (ESI) m / z: 241.0 / 243.0 (M+1). Step 2: Preparation of compound 3-3 To a solution of compound 3-2 (5 g, 20.74 mmol) in methanol (100 mL) was added thionyl chloride (4.94 g, 41.49 mmol) dropwise. The mixture was stirred at 70° C. for 12 hours. Then, water (30 mL) was added to quench the reaction mixture, and methanol was removed by concentration under reduced pressure. Extraction was performed with ethyl acetate (50 mL), and the separated organic layers were washed with water (50 mL), washed with saturated saline (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 3-3. LCMS (ESI) m / z: 255.1 / 257.1 (M+1). Step 3: Preparation of Compound 3-4 Compound 3-3 (1.00 g, 3.92 mmol) was dissolved in DMF (20 mL) at 0° C., sodium hydride (235.21 mg, 5.88 mmol, 60% purity) was added, and the mixture was stirred at 0° C. for 1 h. Then, 2-(trimethylsilyl)ethoxymethyl chloride (980.45 mg, 5.88 mmol) was added, and the mixture was stirred at 20-30° C. for 2 h. The reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (20 mL×2), and the separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=10 / 1-1 / 1) to obtain compound 3-4. LCMS (ESI) m / z: 515.1 / 517.1 (M+1). Step 4: Preparation of Compounds 3-5 Compound 3-4 (0.19 g, 493.09 μmol), compound 1-4 (187.68 mg, 591.70 μmol), sodium carbonate (130.66 mg, 1.23 μmol) and diphenylphosphine ferrocene palladium dichloride (36.08 mg, 49.31 μmol) were mixed in dioxane (4 mL) and water (1 mL), and then the mixture was stirred at 115 °C under microwave conditions for 1 h. Water (30 mL) was added to quench the reaction mixture, and it was extracted with ethyl acetate (30 mL x 2). The separated organic layer was washed with 20 mL of brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to obtain compound 3-5. LCMS (ESI) m / z: 496.3 (M+1). Step 5: Preparation of Compounds 3-6 At 0° C., compound 3-5 (0.55 g, 1.11 mmol) was dissolved in tetrahydrofuran (50 mL) and lithium aluminum tetrahydride (168.45 mg, 4.44 mmol) was added. The mixture was then stirred at 0° C. for 2 h. The reaction mixture was quenched by adding water (4 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 3-6. LCMS (ESI) m / z: 440.2 (M+1). Step 6: Preparation of Compounds 3-7 Compound 3-6 (0.45 g, 1.02 mmol) was dissolved in water (5 mL) and concentrated sulfuric acid (9.2 g, 91.93 mmol) was added. The mixture was then stirred at 60° C. for 12 h. The reaction mixture was quenched by adding aqueous sodium carbonate (100 mL) and extracted with ethyl acetate (30 mL×3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 3-7. LCMS (ESI) m / z: 292.0 (M+1). Step 7: Preparation of Compounds 3-8 Compound 3-7 (0.2 g, 686.47 μmol) and diethyl 2-(ethoxymethylene)malonate (178.12 mg, 823.76 μmol) were dissolved in N-methylpyrrolidone (4 mL), degassed and flushed with nitrogen three times. The mixture was stirred at 110 °C for 16 h. Water (30 mL) was added to quench the reaction mixture, extracted with ethyl acetate (30 mL x 2), and the separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 0 / 1) to obtain compound 3-8. LCMS (ESI) m / z: 462.1 (M+1). Step 8: Preparation of Compounds 3-9 Compound 3-8 (0.12 g, 260.02 μmol) was dissolved in polyphosphoric acid (5.00 g). The mixture was then stirred at 80° C. for 4 h. The reaction mixture was quenched by adding saturated aqueous sodium carbonate solution (100 mL) and extracted with ethyl acetate (30 mL×2). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 3-9. LCMS (ESI) m / z: 416.3 (M+1). Step 9: Preparation of Compound 3 Compound 3-9 (0.02 g, 48.14 μmol) was dissolved in methanol (3 mL) and water (1 mL), and lithium hydroxide monohydrate (4.04 mg, 96.28 μmol) was added. The mixture was then stirred at 20-30° C. for 1 h. The reaction mixture was adjusted to pH=5-6 with 1 M hydrochloric acid, and then concentrated under reduced pressure to obtain a residue. Compound 3 was obtained by purification using preparative HPLC (column: Phenomenex Synergi C18 150×25 mm×10 μm; mobile phase: 0.225% formic acid aqueous solution-acetonitrile; gradient: acetonitrile: 8%-38%). 1H NMR (400 MHz, DMSO-d6) δ = 8.91 (s, 1H), 8.57 - 8.46 (m, 1H), 8.40 (s, 1H), 8.09 - 7.76 (m, 3H), 4.67 - 4.46 (m, 4H), 3.98 - 3.98 (m, 1H), 1.39 - 1.29 (m, 2H), 1.08 - 1.01 (m, 2H). LCMS (ESI) m / z: 388.1 (M+1).

[0129] JPEG2024541618000036.jpg116170 Step 1: Preparation of compound 4-2 Compound 4-1 (10.00 g, 48.20 mmol) was dissolved in dichloromethane (200 mL), and (Boc)2O (26.30 g, 120.51 mmol, 27.69 mL) and DMAP (588.90 mg, 4.82 mmol) were added. The mixture was then stirred at 15-25°C for 2 h. The reaction solution was washed with saturated aqueous sodium bicarbonate (50 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 4-2. LCMS (ESI) m / z: 250.9 / 252.9 (M-100-56+1). Step 2: Preparation of compound 4-3 Potassium carbonate (20.34 g, 147.17 mmol) was added to a solution of compound 4-2 (20.00 g, 49.06 mmol) in methanol (100 mL). The mixture was stirred at 20-30° C. for 2 hours. Methanol was removed by vacuum concentration, and then water (100 mL) and ethyl acetate (50 mL) were added to quench the reaction mixture, and the mixture was filtered to collect filter cake 1. The filtrate was extracted with ethyl acetate (30 mL×2), and the separated organic layer was washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Ethyl acetate (15 mL) was added to the obtained crude product, stirred, and filtered to collect filter cake 2. The two filter cakes were combined and dried to obtain compound 4-3. LCMS (ESI) m / z: 250.9 / 252.9 (M-56+1). Step 3: Preparation of compound 4-4 Compound 4-3 (13.2 g, 42.92 mmol) was dissolved in DMF (100 mL), and methyl iodide (7.31 g, 51.50 mmol) and cesium carbonate (41.95 g, 128.75 mmol) were added. The mixture was then stirred at 20-30 °C for 3 h. Water (200 mL) was added to quench the reaction mixture, and the mixture was extracted with ethyl acetate (100 mL x 2). The separated organic layer was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 4-4. LCMS (ESI) m / z: 264.9 / 266.9 (M-56+1). Step 4: Preparation of Compound 4-5 Compound 4-4 (4.94 g, 14.93 mmol), allyltributyltin (4 g, 12.44 mmol), cesium fluoride (4.53 g, 29.85 mmol) and tetrakistriphenylphosphine palladium (1.15 g, 995.03 μmol) were mixed in dioxane (40 mL) and replaced with N2 three times, and then the mixture was stirred at 70 ° C in a nitrogen atmosphere for 5 h. The reaction mixture was quenched by adding an aqueous potassium fluoride solution (50 mL) and stirred for 1 hour, and then filtered, and the filtrate was extracted with ethyl acetate (50 mL × 3), and the separated organic layer was washed with saturated saline (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 ~ 10 / 1) to obtain compound 4-5. LCMS (ESI) m / z: 227.1 / 229.1 (M-56+1). Step 5: Preparation of Compounds 4-7 Compound 4-6 (1.00 g, 3.27 mmol) was dissolved in chloroform (10 mL), N-bromosuccinimide (698.53 mg, 3.92 mmol) and azobisisobutyronitrile (53.71 mg, 0.33 mmol) were added, and the mixture was stirred at 80° C. for 16 hours. The reaction solution was then concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1-1 / 2) to obtain compound 4-7. 1H NMR (400 MHz, CD3OD) δ ppm= 8.90 (s, 1 H), 8.36 (d, J = 8.75 Hz, 1 H), 7.61 (d, J = 8.76 Hz, 1 H), 4.32 - 4.41 (m, 3 H), 2.71 (s, 2 H), 1.40 (t, J = 7.07 Hz, 7 H). JPEG2024541618000037.jpg38170 Step 7: Preparation of Compounds 4-9 Methyltriphenylphosphine bromide (2.85 g, 7.98 mmol) was dissolved in tetrahydrofuran (80 mL), and then potassium tert-butoxide (1 M, 7.98 mL) was added at 0 °C, and the mixture was stirred at 15-25 °C for 0.5 h. Compound 4-8 (1.7 g, 5.32 mmol) was then added, and the mixture was stirred at 15-25 °C for 2 h. Water (200 mL) was added to quench the reaction mixture, and the mixture was extracted with ethyl acetate (50 mL × 3). The separated organic layer was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 1) to obtain compound 4-9. LCMS (ESI) m / z: 318.1 (M+1). Step 8: Preparation of Compounds 4-10 Compound 4-9 (1.5 g, 4.72 mmol), 2-di-t-butylphosphino-2',4',6'-triisopropylbiphenyl (225.03 mg, 472.05 μmol), tricyclohexylphosphine (132.38 mg, 472.05 μmol), bis(pinacolato)diboron (1.80 g, 7.08 mmol), potassium acetate (926.53 mg, 9.44 mmol) and tris(dibenzylideneacetone)dipalladium (432.26 mg, 472.05 μmol) were mixed in dioxane (10 mL) and purged with N2 three times. The mixture was then stirred at 100 °C under nitrogen atmosphere for 2 h. The reaction mixture was quenched by adding water (50 mL) and extracted with ethyl acetate (30 mL x 3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give compound 4-10. LCMS (ESI) m / z: 410.3 (M+1). Step 9: Preparation of Compounds 4-11 Compound 4-10 (0.5 g, 1.22 mmol), compound 4-5 (345.44 mg, 1.12 mmol), potassium carbonate (337.68 g, 2.44 mmol), 2-di-t-butylphosphino-2',4',6'-triisopropylbiphenyl (58.24 mg, 122.17 μmol), tricyclohexylphosphine (34.26 mg, 122.17 μmol) and tris(dibenzylideneacetone)dipalladium (111.87 mg, 122.17 μmol) were mixed in dioxane (10 mL) and water (2 mL), and the atmosphere was replaced with N2 three times. The mixture was then stirred at 100 °C under nitrogen atmosphere for 1.5 h. The reaction mixture was quenched by adding water (50 mL) and extracted with ethyl acetate (30 mL x 3). The separated organic layer was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. Compound 4-11 was obtained by purification by preparative HPLC (column: Phenomenex luna C18 150 x 40 mm x 15 μm; mobile phase: 0.225% aqueous formic acid-acetonitrile; gradient: acetonitrile: 57% to 87%). LCMS (ESI) m / z: 530.2 (M+1). 1 H NMR (400 MHz, CDCl3) δ = 8.70 (s, 1H), 8.47 (d, J = 8.3 Hz, 1H), 8.13 - 8.06 (m, 1H), 7.66 (s, 1H), 7.22 (d, J = 8.0 Hz, 1H), 6.92 - 6.81 (m, 1H), 5.75 (tdd, J = 6.6, 10.2, 16.9 Hz, 1H), 5.34 - 5.26 (m, 1H), 5.09 - 4.83 (m, 1H), 4.43 (q, J = 7.0 Hz, 2H), 3.84 - 3.74 (m, 1H), 3.45 (s, 3H), 3.18 - 3.00 (m, 2H), 1.58 - 1.55 (m, 9H), 1.44 (t, J = 7.1 Hz, 3H), 1.30 - 1.24 (m, 3H), 1.15 - 1.08 (m, 2H), 0.91 - 0.84 (m, 2H). Step 10: Preparation of Compounds 4-12 Compound 4-11 (0.04 g, 75.53 μmol) was dissolved in dichloromethane (2 mL), and Hoveyda-Grubbs second generation catalyst (4.73 mg, 7.55 μmol) was added. The mixture was then stirred at 40° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=10 / 1 to 0 / 1) to give compound 4-12. LCMS (ESI) m / z: 502.3 (M+1). Step 11: Preparation of Compounds 4-13 Compound 4-12 (0.05 g, 99.69 μmol) was dissolved in dioxane (0.5 mL), and hydrochloric acid / dioxane solution (4 M, 0.5 mL) was added. The mixture was then stirred at 10-20° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give compound 4-13. LCMS (ESI) m / z: 402.2 (M+1). Step 12: Preparation of Compound 4 Compound 4-13 (0.04 g, 99.64 μmol) was dissolved in methanol (1 mL) and water (0.2 mL), and sodium hydroxide (7.97 mg, 199.27 μmol) was added. The mixture was then stirred at 10-20° C. for 2 hours. The reaction mixture was adjusted to pH=5-6 with acetic acid, and then concentrated under reduced pressure to obtain a residue. Compound 4 was obtained by purification using preparative HPLC (column: Phenomenex luna C18 150×25 mm×10 μm; mobile phase: 0.225% formic acid aqueous solution-acetonitrile; gradient: acetonitrile: 4-34%). 1H NMR (400 MHz, DMSO-d6) δ = 15.09 (s, 1H), 8.89 (s, 1H), 8.38 (s, 1H), 8.28 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.08 (d, J = 9.8 Hz, 1H), 6.86 (br d, J = 4.9 Hz, 1H), 6.39 (s, 1H), 6.16 (td, J = 7.1, 9.8 Hz, 1H), 4.37 (br t, J = 4.4 Hz, 1H), 3.45 - 3.39 (m, 2H), 2.83 (d, J = 4.9 Hz, 3H), Obtained 1.28 - 0.77 (m, 4H). LCMS (ESI) m / z: 374.1 (M+1).

[0130] JPEG2024541618000038.jpg100170 Step 1: Preparation of compound 5-2 Silver carbonate (5.41 g, 19.61 mmol) was added to a solution of compound 5-1 (3.50 g, 15.08 mmol) and methyl iodide (3.21 g, 22.63 mmol, 1.41 mL) in toluene (50 mL). The mixture was stirred at 100° C. for 1.5 hours. The mixture was then cooled to room temperature, diluted with ethyl acetate (50 mL), filtered, and the mother liquor was concentrated to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=20 / 1 to 10 / 1) to obtain compound 5-2. LCMS (ESI) m / z: 246 / 248 (M+1); 1 H NMR (400 MHz, CDCl3) δ= 8.37 (s,1 H),7.10 (s,1 H),3.97 (s,3 H),3.95 (s,3 H). Step 2: Preparation of compound 5-3 Lithium aluminum tetrahydride (466.61 mg, 12.29 mmol) was added batchwise to a solution of 5-2 (2.75 g, 11.18 mmol) in tetrahydrofuran (40 mL) at 0° C. The mixture was stirred at 0° C. for 0.5 h. The reaction mixture was quenched by adding sodium sulfate decahydrate (5.00 g) at 0° C., and then filtered. The mother liquor was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=5 / 1-3 / 1) to obtain compound 5-3. LCMS (ESI) m / z: 218 / 220 (M+1). Step 3: Preparation of compound 5-4 Sodium hydride (238.46 mg, 5.96 mmol, 60% purity) was added to a solution of compound 5-3 (1.00 g, 4.59 mmol) in tetrahydrofuran (15 mL) at 0° C., and then compound 4-7 (1.76 g, 4.59 mmol) was added and the mixture was stirred at 0° C. for 3.5 h. The reaction was quenched by adding 15 mL of saturated aqueous ammonium chloride solution and extracted with ethyl acetate (15 mL×2). The combined organic layers were washed with brine (15 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=2 / 1 to 1 / 1) to give compound 5-4. LCMS (ESI) m / z: 521 / 523 (M+1). Step 4: Preparation of compound 5-5 Compound 5-4 (0.1 g, 0.19 mmol), bis(pinacolato)diboron (97.33 mg, 0.38 mmol), potassium acetate (37.62 g, 0.38 mmol), bis(triphenylphosphine)palladium(II) dichloride (14.02 mg, 19.16 μmol) were mixed in ethylene glycol dimethyl ether (2 mL), and the atmosphere was replaced with N2 three times, and then the mixture was stirred at 80 ° C. in a nitrogen atmosphere for 16 h. Further, bis(triphenylphosphine)palladium(II) dichloride (14.02 mg, 19.16 μmol), sodium carbonate (40.62 mg, 0.38 mmol) and water (0.2 mL) were added to the reaction mixture, and then the mixture was stirred at 80 ° C. in a nitrogen atmosphere for 20 h. The reaction mixture was concentrated under reduced pressure to remove the solvent, and a residue was obtained. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1 to 0 / 1) to give compound 5-5. LCMS (ESI) m / z: 407 (M+1). Step 5: Preparation of Compound 5 Lithium hydroxide monohydrate (10.32 mg, 246.04 μmol) was added to a solution of compound 5-5 (25 mg, 61.51 μmol) in methanol (1 mL) and water (0.25 mL) at 20° C. The mixture was stirred at 20° C. for 3 h and concentrated under reduced pressure to obtain a residue, which was purified by preparative HPLC (column: Phenomenex C1875×30 mm×3 μm; mobile phase: 0.225% aqueous formic acid-acetonitrile; gradient: acetonitrile: 32% to 62%) to obtain compound 5. LCMS (ESI) m / z: 309 (M+1); 1 H NMR (400 MHz, DMSO-d6) δ= 8.88 - 8.97 (m, 1 H), 8.61 - 8.68 (m, 1 H), 8.44 - 8.53 (m, 1 H), 7.90 - 8.01 (m, 1 H), 7.10 - 7.17 (m, 1 H), 4.66 - 4.78 (m, 2 H), 4.44 - 4.59 (m, 3 H), 3.95 - 4.02 (m, 3 H), 1.30 - 1.38 (m, 2 H), 1.04 (br d, J = 8.19 Hz, 2 H).

[0131] JPEG2024541618000039.jpg119170 Step 1: Preparation of compound 6-2 Compound 6-1 (1.72 g, 13.86 mmol) was dissolved in acetonitrile (17.2 mL), NBS (2.47 g, 13.86 mmol) was added at 0-20°C, and the mixture was stirred under nitrogen atmosphere for 3 hours. The reaction solution was quenched by adding water (20 mL) and diluted with ethyl acetate (20 mL). After dilution, the mixture was extracted with ethyl acetate (20 mL x 2), and the combined organic phase was washed with saturated saline (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0-1 / 1) to obtain compound 6-2. LCMS (ESI) m / z: 203.05 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 7.87 (s, 1H), 6.67 (s, 1H), 6.11 (s, 2H), 5.46 (t, J = 5.6 Hz, 1H), 4.35 (d, J = 5.6 Hz, 2H). Step 2: Preparation of compound 6-3 Compound 6-2 (30 g, 147.76 mmol) and imidazole (15.09 g, 221.64 mmol) were dissolved in DMF (250 mL) solution, then TBSCl (33.40 g, 221.64 mmol, 27.16 mL) was dissolved in DMF (50 mL) and slowly added dropwise to the reaction solution over 20 minutes at 25 ° C., and stirred at 25 ° C. for 3 hours. The reaction solution was diluted with water (100 mL), extracted with ethyl acetate (50 mL × 2), the combined organic phase was washed with saturated saline (50 mL × 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, the crude product was stirred with petroleum ether (100 mL), filtered, the filter cake was collected and dried to obtain compound 6-3. LCMS (ESI) m / z: 319.1 (M+1). Step 3: Preparation of compound 6-4 To a solution of compound 6-3 (3 g, 9.45 mmol) in DMF (30 mL), NaH (1.51 g, 37.82 mmol) and methyl iodide (6.71 g, 47.27 mmol, 2.94 mL) were added in sequence. The mixture was stirred at 0° C. for 5 hours. The reaction solution was quenched with saturated ammonium chloride solution (50 mL), diluted with water (20 mL), extracted with ethyl acetate (20 mL×2), and the combined organic phase was washed with saturated saline (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. Compound 6-4 was obtained by silica gel column chromatography (petroleum ether / ethyl acetate=100 / 1). LCMS (ESI) m / z: 346.9 (M+1). Step 4: Preparation of compound 6-5 Triethylamine hydrofluoride (4.48 g, 27.80 mmol, 4.53 mL) was added to a solution of compound 6-4 (1.92 g, 5.56 mmol) in dichloromethane (20 mL) and stirred at 25 ° C. in a nitrogen atmosphere for 2 hours. After diluting the reaction solution with water (5 mL), it was extracted with ethyl acetate (5 mL × 2), and the mixed organic phase was washed with saturated saline (5 mL × 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude compound. The crude product was subjected to silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 5 / 1) to obtain compound 6-5. 1 H NMR (400 MHz, DMSO-d6) δ = 8.09 (s, 1H), 6.83 (s, 1H), 4.44 (s, 2H), 3.05 (s, 6H). Step 5: Preparation of compound 6-6 At 0°C, sodium hydride (328.88mg, 8.22mmol, 60% purity) and compound 4-7 (1.58g, 4.11mmol) were added in sequence to a solution of compound 6-5 (0.95g, 4.11mmol) in DMF (10mL), and the mixture was stirred for 6 hours. The reaction solution was quenched with saturated ammonium chloride solution (10mL), diluted with water (10mL), extracted with ethyl acetate (10mL x 2), and the mixed organic phase was washed with saturated saline (10mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was subjected to silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 1 / 2) to obtain compound 6-6. 1 H NMR (400 MHz, DMSO-d6) δ = 8.60 (s, 1H), 8.14 (d, J = 8.6 Hz, 1H), 8.02 (s, 1H), 7.57 (d, J = 8.7 Hz, 1H), 6.51 (s, 1H), 5.39 (s, 2H), 4.44 (s, 2H), 4.24 (q, J = 7.1 Hz, 3H), 2.94 (s, 6H), 1.29 (t, J = 7.1 Hz, 3H), 1.17 (br d, J = 7.1 Hz, 3H), 0.90 - 0.85 (m, 2H). Step 6: Preparation of Compounds 6-7 At room temperature, compound 6-6 (0.5 g, 934.88 μmol), bis(pinacolato)diboron (712.20 mg, 2.80 mmol), potassium pivalate (327.73 mg, 2.34 mmol), and tetrakistriphenylphosphinepalladium (108.03 mg, 93.49 μmol) were dissolved in ethylene glycol dimethyl ether (5 mL), heated to 90 ° C, and stirred for 18 hours. After diluting the reaction solution with water (10 mL), it was extracted with ethyl acetate (20 mL), and the organic phase was washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 1 / 1) to obtain compound 6-7. LCMS (ESI) m / z: 582.3 (M+1). Step 7: Preparation of trifluoroacetate salts of compounds 6-8 Compound 6-7 (390 mg, 670.23 μmol), potassium carbonate (231.58 mg, 1.68 mmol), tetrakistriphenylphosphine palladium (24.71 mg, 67.02 μmol), 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (63.90 mg, 134.05 μmol) were dissolved in water (0.4 mL) and ethylene glycol dimethyl ether (4 mL), heated to 90 ° C., and stirred for 15 hours. After diluting the reaction solution with water (5 mL), it was extracted with ethyl acetate (5 mL × 2), and the mixed organic phase was washed with saturated saline (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25mm*4μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 24%-44%) to give the trifluoroacetate salt of compound 6-8. LCMS (ESI) m / z: 420.2 (M+1). Step 8: Preparation of Compound 6 and the Hydrochloride Salt of Compound 6 Method 1: At 0°C, sodium hydroxide (14.30mg, 357.59μmol) was added to a mixed solution of compound 6-8 (30mg, 71.52μmol) in methanol (0.6mL) and water (0.3mL), and the mixture was stirred at 20°C under nitrogen atmosphere for 15 hours. After filtration, the filtrate was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: 10mM ammonium bicarbonate aqueous solution-acetonitrile; gradient: acetonitrile: 24%~54%) to obtain compound 6. LCMS (ESI) m / z: 392.1 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 8.90 (s, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.51 (s, 1H), 4.77 (br s, 2H), 4.56 - 4.52 (m, 2H), 3.91 - 4.02 (m, 1H), 3.15 (s, 6H), 1.22-1.45 (m, 4H). Method 2: At 0°C, an aqueous solution (10mL) of sodium hydroxide (600.76mg, 15.02mmol) was added to compound 6-8 (0.63g, 1.50mmol) in methanol (20mL) and stirred at 20-30°C for 15 hours. After filtration, the filter cake was collected to obtain a crude product. At room temperature, the crude product was added to a mixture of hydrochloric acid (12M, 122.63μL) and aqueous solution (4mL) and stirred for 16 hours. After filtering the reaction solution, the filter cake was collected and dried to obtain the hydrochloride salt of compound 6. LCMS (ESI) m / z: 392.1 (M+1).

[0132] JPEG2024541618000040.jpg156170 Step 1: Preparation of compound 7-2 At 0°C, sodium hydride (322.22mg, 8.06mmol) was added to a solution of compound 7-1 (0.50g, 4.03mmol) in DMF (5mL), and after 10 minutes, compound 4-7 was added to the reaction solution and stirred for 6 hours. The reaction solution was quenched with saturated ammonium chloride solution (10mL), extracted with ethyl acetate (10mL), washed with saturated saline (10mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. Compound 7-2 was obtained by silica gel column chromatography (dichloromethane / methanol=100 / 3). LCMS (ESI) m / z: 428.2 (M+1). Step 2: Preparation of compound 7-3 At 0°C, bromosuccinimide (0.61g, 3.41mmol) was added to a solution of compound 7-2 (1.46g, 3.41mmol) in dichloromethane (20mL), and the mixture was stirred at 0°C for 2 hours. The reaction solution was concentrated, diluted with water (10mL), and then extracted with dichloromethane (10mL x 2). The mixed organic phase was washed with saturated saline (10mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude compound. Compound 7-3 was obtained by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 0 to 100 / 3). LCMS (ESI) m / z: 508.1 (M+1). Step 3: Preparation of compound 7-4 To a solution of compound 7-3 (390.85 mg, 771.24 μmol) in dichloromethane (6 mL), Boc2O (0.42 mg, 1.93 mmol, 0.44 mL) and 4-dimethylaminopyridine (9.42 mg, 77.12 μmol) were added and stirred at 20-25°C for 2 hours. The reaction solution was diluted with water (5 mL), extracted with dichloromethane (5 mL x 2), and the combined organic phase was washed with saturated saline (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 7-4. LCMS (ESI) m / z: 708.1 (M+1). Step 4: Preparation of compound 7-5 To a solution of compound 7-4 (0.05 g, 70.72 μmol) in ethylene glycol dimethyl ether (1 mL), bis(pinacolato)diboron (35.92 mg, 141.44 μmol), potassium pivalate (24.79 mg, 176.80 μmol) and tetrakistriphenylphosphine palladium (2.61 mg, 7.07 μmol) were added in sequence and stirred at 90° C. for 15 hours. The crude product, compound 7-5, was obtained as a reaction solution and used in the next step as it was. LCMS (ESI) m / z: 672.3 (M+1). Step 5: Preparation of compound 7-6 Crude compound 7-5 (47.52 mg, 70.72 μmol), potassium carbonate (24.44 mg, 176.80 μmol), tetrakistriphenylphosphine palladium (2.61 mg, 7.07 μmol), 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (6.74 mg, 14.14 μmol) were dissolved in water (0.1 mL) and ethylene glycol dimethyl ether (1 mL), purged with nitrogen three times, heated to 90° C., and stirred for 15 hours. The reaction solution was filtered and concentrated under reduced pressure to obtain compound 7-6. LCMS (ESI) m / z: 592.2 (M+1). Step 6: Preparation of the trifluoroacetate salt of compound 7-7 and compound 7-7 Trifluoroacetic acid (821.20 mg, 7.20 mmol, 533.25 μL) was added to a solution of compound 7-6 (41.84 mg, 70.72 μmol) in dichloromethane (1 mL) and stirred for 2 hours. The mixture was worked up in batches. Method 1: The reaction solution was concentrated under reduced pressure to obtain the trifluoroacetate salt of compound 7-7. Method 2: The reaction solution was concentrated under reduced pressure to obtain a crude product, which was adjusted to pH 8.0 with saturated sodium carbonate solution and extracted with dichloromethane. The organic phases were combined and concentrated under reduced pressure to obtain compound 7-7. LCMS (ESI) m / z: 392.1 (M+1). Step 7: Preparation of the trifluoroacetate salt of compound 7 and the hydrochloride salt of compound 7 Method 1: At 0°C, sodium hydroxide (26.52mg, 662.97μmol) was added to a solution of crude compound 7-7 (25.95mg, 66.30μmol) in methanol (1mL) and water (0.5mL), and the mixture was stirred at 20°C for 15 hours under nitrogen atmosphere. The crude compound was obtained by concentrating under reduced pressure, and the crude compound was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25mm*4μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 17%~37%) to obtain the trifluoroacetate salt of compound 7. LCMS (ESI) m / z: 364.1 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 8.90 (s, 1H), 8.47 (d, J = 8.4 Hz, 1H), 8.41 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 6.91 (s, 1H), 4.77 (br s, 2H), 4.51 (s, 3H), 1.32 (br d, J = 6.4 Hz, 2H), 1.02 (br s, 2H). Method 2: At room temperature, an aqueous solution (5 mL) of sodium hydroxide (102.18 mg, 2.55 mmol) was added to a solution of crude compound 7-7 (1 g, 2.55 mmol) in methanol (10 mL), and the mixture was stirred at 20-50 °C for 36 h. The mixture was filtered and the filter cake was collected to obtain the crude product. Hydrochloric acid (12 M, 2 mL) was added to the aqueous solution (4 mL) of the crude product, and the mixture was stirred for 16 h. After filtering the reaction solution, the filter cake was collected and dried to obtain the hydrochloride salt of compound 7. LCMS (ESI) m / z: 364.1 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 8.91 (s, 1H), 8.49 (d, J = 8.3 Hz, 1H), 8.42 (s, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.05 (s, 1H), 4.81 (s, 2H), 4.55 (s, 2H), 4.52 - 4.43 (m, 1H), 1.36 - 1.28 (m, 2H), 1.07 - 0.99 (m, 2H).

[0133] JPEG2024541618000041.jpg181170 Step 1: Preparation of compound 8-2 At 20°C, compound 8-1 (1.00g, 5.39mmol), N-methylbenzylamine (979.32mg, 8.08mmol, 1.04mL) was dissolved in dioxane (20mL), cesium carbonate (5.27g, 16.16mmol), chloro[(tri-t-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (276.07mg, 538.77μmol) were added, the mixture was stirred at 90°C for 16 hours, the compound was filtered and concentrated, and subjected to silica gel column chromatography (petroleum ether / ethyl acetate=50 / 1 to 30 / 1) to obtain compound 8-2. LCMS (ESI) m / z: 271.2 (M+1). 1 H NMR (400 MHz, CDCl3) δ = 8.15 (d, J = 5.0 Hz, 1H), 7.32 - 7.23 (m, 4H), 7.21 - 7.12 (m, 2H), 4.27 (s, 2H), 3.84 (s, 3H), 2.67 (s, 3H), 2.42 (s, 3H). Step 2: Preparation of compound 8-3 Compound 8-2 (200 mg, 739.85 μmol) was dissolved in tetrahydrofuran (3 mL) solution, and lithium aluminum tetrahydride (33.70 mg, 887.82 μmol) was added at 0°C. The mixture was stirred at 0-25°C for 2 hours, and water (0.034 mL) and 15% aqueous sodium hydroxide solution (0.034 mL) were added to the reaction solution, and water (0.10 mL) was added to quench the reaction. Anhydrous magnesium sulfate was added, filtered and concentrated to obtain a crude compound, which was subjected to silica gel column chromatography (petroleum ether / ethyl acetate: 3 / 1) to obtain compound 8-3. LCMS (ESI) m / z: 243.1 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 8.09 (d, J = 5.0 Hz, 1H), 7.33 (d, J = 4.6 Hz, 4H), 7.28 - 7.20 (m, 1H), 7.08 (d, J = 5.0 Hz, 1H), 5.29 (t, J = 5.4 Hz, 1H), 4.50 (d, J = 5.4 Hz, 2H), 4.22 (s, 2H), 2.63 (s, 3H), 2.19 (s, 3H). Step 3: Preparation of compound 8-4 Compound 8-3 (800 mg, 3.30 mmol) was dissolved in a mixed solvent of ethanol (3 mL) and acetic acid (3 mL), then 80 mg Pd / C (10% purity) was added, a hydrogen balloon was set in the reaction flask, and the reaction system was replaced three times, filled with hydrogen, and reacted by stirring at 15 to 25 for 3 hours, filtered and concentrated, water (50 mL) was added, extracted with ethyl acetate (25 mL x 2), the organic phase was washed with water (15 mL x 2), and then the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 8-4. LCMS (ESI) m / z: 153.1 (M+1) Step 4: Preparation of compound 8-5 Compound 8-4 (156 mg, 1.03 mmol) was dissolved in DMF (1 mL), and NaH (82.00 mg, 2.05 mmol, 60% purity) was added at 0-5 ° C., and the mixture was stirred for 0.5 hours. Compound 4-7 (413.99 mg, 1.08 mmol) was then added, and the mixture was stirred for 3 hours at 0-5 ° C. to react. A saturated aqueous solution of ammonium chloride (1 mL) was added to quench the reaction, and water (50 mL) was added, followed by extraction with ethyl acetate (25 mL × 2). The organic phase was washed with saturated saline (25 mL × 2), filtered, dried over anhydrous sodium sulfate, and the filtrate was concentrated under reduced pressure to obtain crude compound 8-5. LCMS (ESI) m / z: 456.1 (M+1). Step 5: Preparation of the trifluoroacetate salt of compound 8-6 Compound 8-5 (330 mg, 723.79 μmol) was dissolved in DCM (3 mL), N-bromosuccinimide (128.82 mg, 723.79 μmol) was added at 0°C, and the mixture was stirred at 0-5°C for 1 hour. The mixture was concentrated and the crude product was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25 mm*4 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 32%-52%) to obtain the trifluoroacetate salt of compound 8-6. LCMS (ESI) m / z: 536.0 (M+1). Step 6: Preparation of Compound 8-7 Compound 8-6 trifluoroacetate (90mg, 168.28μmol) and bis(pinacolato)diboron (85.46mg, 336.56μmol) were dissolved in ethylene glycol dimethyl ether (5mL), then potassium pivalate (47.19mg, 336.56μmol) and tetrakistriphenylphosphinepalladium (19.45mg, 16.83μmol) were added, and the mixture was replaced with nitrogen three times and stirred at 90℃ for 12 hours to obtain a crude product containing compound 8-7, which was used in the next step as it was. LCMS (ESI) m / z: 582.5 (M+1). Step 7: Preparation of compound 8-8 The crude reaction solution containing compound 8-7 (97.9 mg, 168.24 μmol) was added to potassium carbonate (46.51 mg, 336.49 μmol), tetrakistriphenylphosphine palladium (19.44 mg, 16.82 μmol), 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (16.04 mg, 33.65 μmol) dissolved in ethylene glycol dimethyl ether (2 mL) and water (0.2 mL), and reacted at 90 ° C. for 2 hours. The mixture was concentrated, diluted with saturated saline (30 mL), extracted with ethyl acetate (30 mL × 2), washed with saturated saline (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude compound 8-8. LCMS (ESI) m / z: 420.2 (M + 1). Step 8: Preparation of the trifluoroacetate salt of compound 8 Compound 8-8 (95 mg, 226.48 μmol) was dissolved in methanol (3 mL), and then water (1 mL) and NaOH (54.35 mg, 1.36 mmol) were added, and the mixture was stirred at 15-20° C. for 12 hours to react. The mixture was filtered and concentrated to obtain a crude product, which was purified by preparative HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 13%-33%) to obtain the trifluoroacetate salt of compound 8. LCMS (ESI) m / z: 392.1 (M+1). 1 H NMR (400 MHz, CD3OD) δ = 9.09 (s, 1H), 8.64 (d, J = 8.3 Hz, 1H), 8.15 (s, 1H), 7.85 (d, J = 8.3 Hz, 1H), 4.99 - 4.95 (s, 2H), 4.80 - 4.75 (s, 2H), 4.45 (tt, J = 3.5, 7.0 Hz, 1H), 3.21 (s, 3H), 2.42 (s, 3H), 1.52 - 1.45 (m, 2H), 1.12 - 1.03 (m, 2H).

[0134] JPEG2024541618000042.jpg172170 Step 1: Preparation of compound 9-2 Compound 9-1 (2 g, 13.06 mmol) was added to a mixed solvent of ethanol (125 mL) and dichloromethane (20 mL), then NaBH4 (1.51 g, 39.97 mmol) was added, and the mixture was stirred at 15-20 ° C for 12 hours. The reaction solution was filtered and concentrated, and acetone (20 mL) was added to the filtrate under ice bath, and then 2M dilute hydrochloric acid was added until bubbles were no longer generated, and saturated sodium bicarbonate solution was added to adjust the pH to 8, and the mixture was filtered, the filtrate was concentrated, and ethanol (50 mL) was added, and the mixture was stirred at 15-20 ° C for 0.5 hours, filtered, concentrated, and filtrated to obtain compound 9-2. 1 H NMR (400 MHz, DMSO-d6) δ = 8.20 (d, J = 4.9 Hz, 1H), 6.66 (d, J = 5.0 Hz, 1H), 6.50 (br s, 2H), 5.75 - 5.00 (br s, 1H), 4.30(s, 2H). Step 2: Preparation of compound 9-3 Compound 9-2 (0.87 g, 4.17 mmol) was dissolved in DMF (10 mL), and NaH (667.47 mg, 16.69 mmol) was added at 0° C. and stirred for 0.5 hours. Compound 4-7 (1.60 g, 4.17 mmol) was added and stirred at 0-5° C. for 3 hours. Saturated saline (100 mL) was added for quenching, and the mixture was dried over sodium sulfate, filtered, and the filtrate was concentrated to obtain compound 9-3. LCMS (ESI) m / z: 429.1 (M+1). Step 3: Preparation of compound 9-4 Compound 9-3 (0.55 g, 1.28 mmol) was dissolved in DCM (5 mL), and NBS (228.25 mg, 1.28 mmol) was added at 0° C. and the mixture was stirred for 1 hour to react. Compound 9-4 was obtained by silica gel flash column chromatography (dichloromethane / methanol=50 / 1). LCMS (ESI) m / z: 508.9 (M+1). Step 4: Preparation of compound 9-5 Compound 9-4 (0.8 g, 1.58 mmol), Boc2O (1.20 g, 5.51 mmol, 1.27 mL), and DMAP (19.25 mg, 157.55 μmol) were dissolved in DCM (3 mL) and reacted with stirring at 10-25 °C for 12 h. The reaction solution was concentrated and subjected to silica gel flash column chromatography (dichloromethane / methanol = 50 / 1) to obtain compound 9-5. LCMS (ESI) m / z: 709.2 (M+1). Step 5: Preparation of compound 9-6 Compound 9-5 (100 mg, 141.24 μmol), bis(pinacolato)diboron (71.73 mg, 282.49 μmol), tetrakistriphenylphosphinepalladium (16.32 mg, 14.12 μmol), potassium pivalate (39.61 mg, 282.49 μmol) were added to DME (2 mL), stirred at 90 ° C for 12 hours, cooled to room temperature, potassium carbonate (39.02 mg, 282.35 μmol), tetrakistriphenylphosphinepalladium (16.32 mg, 14.12 μmol), 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl (13.46 mg, 28.24 μmol), H2O (0.2 mL) were added, and the mixture was reacted at 90 ° C for 2 hours. The reaction solution was concentrated to obtain compound 9-6. LCMS (ESI) m / z: 593.3 (M+1). Step 6: Preparation of Compound 9-7 Compound 9-6 (83 mg, 140.05 μmol) was added to a mixed solvent of MeOH (1 mL) and HO (3 mL), sodium hydroxide (33.61 mg, 840.31 μmol) was added, and the mixture was stirred at 15-20° C. for 12 hours to react. The reaction solution was concentrated to give compound 9-7. LCMS (ESI) m / z: 565.4 (M+1). Step 7: Preparation of the trifluoroacetate salt of compound 9 Compound 9-7 (79 mg, 139.93 μmol) was added to a mixed solvent of DCM (1 mL) and TFA (770.00 mg, 6.75 mmol), and the mixture was stirred at 15-20 ° C for 6 hours to react. The reaction solution was concentrated, and the crude product was dissolved in a mixed solvent of DMF (5 mL) and TFA (200 μL), and separated and purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase: [0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 30%-50%), MeOH (1 mL) was added, and the mixture was stirred at 15-20 ° C for 1 hour, filtered, and the filter cake was rinsed with MeOH (0.5 mL) and dried under reduced pressure to obtain the trifluoroacetate salt of compound 9. LCMS (ESI) m / z: 365.1 (M + 1).

[0135] JPEG2024541618000043.jpg126170 Step 1: Preparation of trifluoroacetate salt of compound 10-1 At 0°C, compound 5-bromo-2-methylpyridine-4-methanol (525.28mg, 2.60mmol) was dissolved in DMF (10mL), NaH (415.96mg, 10.40mmol, 60% purity) was slowly added, and the mixture was allowed to react for 0.5 hours. Then, compound 4-7 (1g, 2.60mmol) was added at 0°C, and the mixture was stirred at 0°C for 1 hour. The reaction solution was quenched by adding it to a saturated aqueous ammonium chloride solution (20mL) at 0°C, diluted with water (20mL), and then extracted with ethyl acetate (90mL). The organic layer was washed with saturated saline (60mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Phenomenex Luna 150×40 mm×15 μm; mobile phase: 0.05% aqueous trifluoroacetic acid and acetonitrile; the proportion of acetonitrile in the mobile phase was 21% to 51%) to obtain the trifluoroacetate salt of compound 10-1. LCMS (ESI) m / z: 507.1 (M+1). 1H NMR (400 MHz, CD3OD) δ ppm 0.81 - 0.92 (m, 2 H) 1.17 (br d, J=6.24 Hz, 3 H) 1.26 (t, J=7.09 Hz, 3 H) 2.42 (s, 3 H) 4.22 (d, J=7.09 Hz, 3 H) 4.54 (s, 2 H) 5.49 (s, 2 H) 7.35 (s, 1 H) 7.42 (d, J=8.68 Hz, 1 H) 8.13 (d, J=8.68 Hz, 1 H) 8.47 (s, 1 H) 8.71 (s, 1 H). Step 2: Preparation of the trifluoroacetate salt of compound 10-2 The trifluoroacetate salt of compound 10-1 (252 mg, 498.23 μmol), bis(pinacolato)diboron (253.04 mg, 996.47 μmol), potassium pivalate (139.72 mg, 996.47 μmol), and triphenylphosphine palladium (36.74 mg, 99.65 μmol) were mixed in DMF (3 mL), degassed and replaced with nitrogen three times, and the mixture was stirred at 120 °C under nitrogen atmosphere for 16 h. The reaction solution was filtered, and the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna 75 × 30 mm × 3 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 15% to 35%) to obtain the trifluoroacetate salt of compound 10-2. LCMS (ESI) m / z: 391.2 (M+1). 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.94 (br s, 2 H) 1.25 - 1.33 (m, 5 H) 2.65 (s, 3 H) 4.20 - 4.39 (m, 3 H) 4.57 (s, 2 H) 4.66 (s, 2 H) 7.65 (s, 1 H) 7.83 (d, J=8.31 ​​Hz, 1 H) 8.38 (d, J=8.19 Hz, 1 H) 8.67 (s, 1 H) 8.94 (s, 1 H). Step 3: Preparation of the sodium salt of compound 10 A solution of 10-2 trifluoroacetate (50 mg, 128.06 μmol) in anhydrous methanol (0.6 mL) was added with sodium hydroxide (51.22 mg, 1.28 mmol) in water (0.3 mL) at room temperature. The mixture was stirred at 20° C. for 3 h. The mixture was concentrated under reduced pressure to give the crude product. DMF (1 mL) was added to the crude product, stirred for 1 h, filtered, and the filter cake was collected to give the sodium salt of compound 10. LCMS (ESI) m / z: 363.1 (M+1). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.04 (br s, 2 H) 1.34 (br d, J=6.85 Hz, 3 H) 2.62 (s, 3 H) 4.48 - 4.59 (m, 3 H) 4.69 (br s, 2 H) 7.54 (s, 1 H) 8.01 (d, J=8.31 ​​Hz, 1 H) 8.52 (d, J=8.31 ​​Hz, 1 H) 8.91 (d, J=10.03 Hz, 2 H) 14.84 (s, 1 H).

[0136] JPEG2024541618000044.jpg124170 Step 1: Preparation of the trifluoroacetate salt of compound 11-1 At 0°C, compound 3-bromopyridine-4-methanol (2.44g, 12.98mmol) was dissolved in DMF (30mL), NaH (2.08g, 51.91mmol, 60% purity) was slowly added, and the mixture was allowed to react for 0.5 hours. Then, compound 4-7 (4.99g, 12.98mmol) was added at 0°C, and the mixture was stirred at 0°C for 1 hour. The reaction solution was quenched by adding it to a saturated aqueous ammonium chloride solution (100mL) at 0°C, diluted with water (50mL), and then extracted with dichloromethane (150mL). The organic layer was washed with saturated saline (200mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Waters Xbridge 250×80 mm×15 μm; mobile phase: 10 mmol / L aqueous trifluoroacetic acid and acetonitrile; gradient: acetonitrile 40% to 70%) to obtain the trifluoroacetate salt of compound 11-1. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.13 - 1.25 (m, 7 H) 4.39 (s, 2 H) 4.46 (br s, 1 H) 4.54 (s, 2 H) 5.46 (s, 2 H) 7.55 (d, J=8.63 Hz, 1 H) 7.62 (d, J=8.63 Hz, 1 H) 8.11 (dd, J=8.57, 5.19 Hz, 2 H) 8.60 (s, 1 H) 8.77 (s, 1 H). Step 2: Preparation of the trifluoroacetate salt of compound 11-2 The trifluoroacetate salt of compound 11-1 (100 mg, 203.35 μmol), bis(pinacolato)diboron (103.28 mg, 406.70 μmol), potassium pivalate (57.03 mg, 406.70 μmol), and triphenylphosphine palladium (15.00 mg, 40.67 μmol) were mixed in DMF (1 mL), degassed and replaced with nitrogen three times, and the mixture was stirred at 120 °C under nitrogen atmosphere for 16 h. After filtration, the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna 75 × 30 mm × 3 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution and acetonitrile; gradient: acetonitrile 16% to 36%) to obtain the trifluoroacetate salt of compound 11-2. LCMS (ESI) m / z: 377.1 (M+1). Step 3: Preparation of compound 11 A solution of the trifluoroacetate salt of 11-2 (10 mg, 26.57 μmol) in anhydrous methanol (0.6 mL) was added with a solution of sodium hydroxide (10.63 mg, 265.67 μmol) in water (0.3 mL) at room temperature. The mixture was stirred at 20 °C for 3 h. After filtration, the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna 75 × 30 mm × 3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 15% to 35%) to give the trifluoroacetate salt of compound 11. LCMS (ESI) m / z: 349.0 (M+1). 1 H NMR (400 MHz, CDCl3) δ ppm 0.98 - 1.11 (m, 2 H) 1.22 - 1.27 (m, 2 H) 4.22 (dt, J=7.21, 3.48 Hz, 1 H) 4.59 (s, 2 H) 4.75 (br s, 2 H) 7.48 (d, J=5.14 Hz, 1 H) 7.83 (d, J=8.31 ​​Hz, 1 H) 8.70 (d, J=8.19 Hz, 1 H) 8.83 (d, J=4.89 Hz, 1 H) 9.00 (d, J=5.87 Hz, 2 H) 14.54 (br d, J=3.55 Hz, 1 H).

[0137] JPEG2024541618000045.jpg84170 Step 1: Preparation of trifluoroacetate salt of compound 12-1 and compound 12-1 At room temperature, acetic acid (27.61 mg, 459.87 μmol) was added to a solution of trifluoroacetate of compound 7-7 (0.12 g, 306.58 μmol), (t-butyldimethylsilyloxy)acetaldehyde (106.88 mg, 613.15 μmol) in dichloromethane (3 mL) and ethanol (1.5 mL), and the mixture was heated to 40° C. and stirred for 1 hour, then cooled to room temperature and sodium cyanoborohydride (57.80 mg, 919.73 μmol) was added, followed by further reaction at 40° C. for 1 hour. The workup was carried out in multiple batches. Method 1: The reaction solution was concentrated under reduced pressure, and then purified by preparative HPLC (column: 3_Phenomenex Luna C18 70*30mm*3μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution and acetonitrile; gradient: acetonitrile 37%-57%) to obtain the trifluoroacetate salt of compound 12-1. Method 2: The reaction solution was concentrated under reduced pressure, and the crude product was adjusted to pH=8.0 with saturated sodium carbonate solution, and extracted with dichloromethane. The organic phases were combined and concentrated under reduced pressure to obtain compound 12-1. LCMS (ESI) m / z: 436.2 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 12 and the hydrochloride salt of compound 12 Method 1: At room temperature, an aqueous solution (0.3 mL) of sodium hydroxide (55.11 mg, 1.38 mmol) was added to compound 12-1 (0.06 g, 137.78 μmol) in methanol (0.6 mL) and stirred at room temperature for 3 hours. After filtration, the filtrate was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25 mm*4 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 20% to 40%) to obtain the trifluoroacetate salt of compound 12. LCMS (ESI) m / z: 408.2 (M+1). Method 2: At room temperature, an aqueous solution (10 mL) of sodium hydroxide (918.54 mg, 22.96 mmol) was added to a solution of compound 12-1 (1 g, 2.30 mmol) in methanol (20 mL), and the mixture was stirred at 20-50 °C for 36 hours. The mixture was filtered and the filter cake was collected to obtain a crude product. Hydrochloric acid (12 M, 2 mL) was added to an aqueous solution (4 mL) of the crude product (100 mg, 245.45 μmol), and the mixture was stirred for 16 hours. The reaction was filtered and the filter cake was collected and dried to obtain the hydrochloride salt of compound 12. LCMS (ESI) m / z: 408.1 (M+1). 1 H NMR (400 MHz, CD3OD) δ ppm 9.08 (s, 1 H),8.63 (d, J=8.44 Hz, 1 H),8.31 (s, 1 H),7.85 (d, J=8.31 ​​Hz, 1 H),7.18 (s, 1 H),4.96 (br s, 2 H),4.64 (s, 2 H),4.41 - 4.48 (m, 1 H),3.87 (t, J=5.20 Hz, 2 H),3.63 (t, J=5.32 Hz, 2 H),1.44 - 1.51 (m, 2 H),1.05 - 1.11 (m, 2 H).

[0138] JPEG2024541618000046.jpg83170 Step 1: Preparation of the trifluoroacetate salt of compound 13-1 At room temperature, acetic acid (4.60 mg, 76.64 μmol) was added to a solution of compound 7-7 (0.02 g, 51.10 μmol), propionaldehyde (4.45 mg, 76.64 μmol) in dichloromethane (1 mL) and ethanol (0.5 mL), and the mixture was heated to 40 ° C. and stirred for 1 hour, then cooled to room temperature and sodium cyanoborohydride (9.63 mg, 153.29 μmol) was added, and the mixture was reacted at 40 ° C. for 1 hr. The reaction solution was concentrated under reduced pressure, and then purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 28% to 48%) to obtain the trifluoroacetate salt of compound 13-1. LCMS (ESI) m / z: 434.2 (M + 1). Step 2: Preparation of the trifluoroacetate salt of compound 13 At room temperature, a solution of sodium hydroxide (5.07 mg, 126.87 μmol) in water (0.25 mL) was added to the trifluoroacetate salt of compound 13-1 (11 mg, 25.37 μmol) in methanol (0.5 mL) and stirred at room temperature for 16 hours. After filtration, the filtrate was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25 mm*4 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 20% to 40%) to obtain the trifluoroacetate salt of compound 13. LCMS (ESI) m / z: 406.2 (M+1).

[0139] JPEG2024541618000047.jpg80170 Step 1: Preparation of compound 14-1 At room temperature, acetic acid (3.38 mg, 76.65 μmol) was added to a solution of trifluoroacetate (0.02 g, 51.10 μmol) of compound 7-7, acetaldehyde (3.38 mg, 76.65 μmol) in dichloromethane (1 mL) and ethanol (0.5 mL), and the mixture was heated to 30° C. and stirred for 1 hour. The mixture was then cooled to room temperature and sodium cyanoborohydride (9.63 mg, 153.29 μmol) was added, followed by further reaction at 30° C. for 1 hour. The reaction solution was concentrated under reduced pressure to obtain compound 3-9. LCMS (ESI) m / z: 420.1 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 14 At room temperature, an aqueous solution (0.5 mL) of sodium hydroxide (10.22 mg, 255.56 μmol) was added to compound 14-1 (21.44 mg, 51.11 μmol) in methanol (1 mL) and stirred at 30 ° C for 16 hours. After filtration, the filtrate was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution - acetonitrile; gradient: acetonitrile: 23% ~ 43%) to obtain the trifluoroacetate salt of compound 14. LCMS (ESI) m / z: 392.1 (M + 1).

[0140] JPEG2024541618000048.jpg78170 Step 1: Preparation of compound 15-1 At room temperature, acetic acid (6.90 mg, 114.97 μmol) was added to a solution of trifluoroacetate (0.03 g, 76.64 μmol) of compound 7-7, benzaldehyde (16.27 mg, 153.29 μmol) in dichloromethane (1 mL) and ethanol (0.5 mL), and the mixture was heated to 30° C. and stirred for 1 hour. The mixture was then cooled to room temperature, sodium cyanoborohydride (9.63 mg, 153.29 μmol) was added, and the mixture was reacted at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure to obtain crude compound 15-1. LCMS (ESI) m / z: 482.3 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 15 At room temperature, an aqueous solution (1 mL) of sodium hydroxide (24.92 mg, 623.00 μmol) was added to compound 15-1 (60 mg, 124.60 μmol) in methanol (2 mL) and stirred at 30 ° C for 15 hours. After filtration, the filtrate was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 32% to 52%) to obtain the trifluoroacetic acid of compound 15. LCMS (ESI) m / z: 454.2 (M + 1). 1H NMR (400 MHz, CD3OD) δ = 9.08 (s, 1H), 8.64 (d, J = 8.3 Hz, 1H), 8.31 (s, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.54 - 7.34 (m, 6H), 7.26 (s, 1H), 4.98 (s, 2H), 4.72 (s, 2H), 4.65 (s, 2H), 4.44 (td, J = 3.5, 7.2 Hz, 1H), 1.47 (br d, J = 6.5 Hz, 2H), 1.08 (br d, J = 2.6 Hz, 2H).

[0141] JPEG2024541618000049.jpg80170 Step 1: Preparation of compound 16-1 At room temperature, acetic acid (23.01 mg, 383.22 μmol) was added to a solution of trifluoroacetate (0.1 g, 255.48 μmol) of compound 7-7, cyclobutylformaldehyde (42.98 mg, 510.96 μmol) in dichloromethane (10 mL) and methanol (5 mL), and the mixture was heated to 40° C. and stirred for 1 hour. The mixture was then cooled to room temperature and pyridine borane (71.23 mg, 766.44 μmol) was added, and the mixture was further reacted at 40° C. for 40 hours. The reaction solution was quenched with saturated ammonium chloride solution (10 mL), extracted with dichloromethane (10 mL), washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude product 16-1. LCMS (ESI) m / z: 460.2 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 16 At room temperature, an aqueous solution (0.6 mL) of sodium hydroxide (24.92 mg, 623.00 μmol) was added to compound 16-1 (120 mg, 250.69 μmol) in methanol (1.2 mL) and stirred at 40 ° C for 16 hours. After filtration, the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna C18 75 * 30 mm * 3 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 29% to 49%) to obtain the trifluoroacetate salt of compound 16. LCMS (ESI) m / z: 432.2 (M + 1). 1H NMR (400 MHz, DMSO-d6) δ = 8.89 (s, 1H), 8.45 (d, J = 8.3 Hz, 1H), 8.37 (s, 1H), 7.88 (d, J = 8.5 Hz, 1H), 6.97 (br s, 1H), 4.77 (br s, 2H), 4.51 (s, 2H), 4.48 (br d, J = 3.6 Hz, 1H), 3.43 (br d, J = 7.1 Hz, 2H), 2.68 - 2.59 (m, 1H), 2.18 - 2.00 (m, 2H), 1.95 - 1.84 (m, 2H), 1.83 - 1.68 (m, 2H), 1.32 (br d, J = 6.6 Hz, 2H), 1.02 (br s, 2H).

[0142] JPEG2024541618000050.jpg81170 Step 1: Preparation of compound 17-1 At room temperature, acetic acid (23.01 mg, 383.22 μmol) was added to a solution of trifluoroacetate (0.1 g, 255.48 μmol) of compound 7-7, oxa-3-cyclobutylformaldehyde (43.99 mg, 510.96 μmol) in dichloromethane (10 mL) and methanol (5 mL), and the mixture was heated to 40 ° C. and stirred for 1 hour, then cooled to room temperature and pyridine borane (71.23 mg, 766.44 μmol) was added, and the mixture was further reacted at 40 ° C. for 40 hours. The reaction solution was quenched with saturated ammonium chloride solution (10 mL), extracted with dichloromethane (10 mL), washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 17-1. LCMS (ESI) m / z: 462.2 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 17 At room temperature, an aqueous solution (0.5 mL) of sodium hydroxide (8.67 mg, 216.68 μmol) was added to compound 17-1 (10 mg, 21.67 μmol) in methanol (1 mL) and stirred at 40 ° C for 16 hours. After filtration, the filtrate was purified by preparative HPLC (column: 3_Phenomenex Luna C18 75 * 30 mm * 3 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution-acetonitrile; gradient: acetonitrile: 11% to 31%) to obtain the trifluoroacetate salt of compound 17. LCMS (ESI) m / z: 434.1 (M + 1). 1H NMR (400 MHz, DMSO-d6) δ = 9.68 (br d, J = 1.1 Hz, 1H), 8.93 (s, 1H), 8.54 (d, J = 2.2 Hz, 1H), 7.92 - 7.83 (m, 1H), 7.16 (s, 1H), 4.91 - 4.81 (m, 2H), 4.58 (br d, J = 1.3 Hz, 3H), 4.53 - 4.43 (m, 2H), 4.22 - 4.19 (m, 1H), 3.58 (br dd, J = 3.2, 6.9 Hz, 2H), 3.54 - 3.46 (m, 1H), 1.33 - 1.33 (m, 1H), 1.31 (br d, J = 7.6 Hz, 1H), 1.03 (br s, 2H).

[0143] JPEG2024541618000051.jpg74170 Step 1: Preparation of compound 18-1 At 20°C, compound 7-7 trifluoroacetate (20mg, 51.10μmol), N-Boc-3-formylazetidine (14.20mg, 76.64μmol) were dissolved in dichloromethane (1mL) and water (0.5mL), glacial acetic acid (4.60mg, 76.64μmol) was added, and the mixture was stirred at 50°C for 16 hours. At room temperature, sodium cyanoborohydride (9.63mg, 153.29μmol) was added, and the mixture was stirred at 20°C for 5 hours, and then heated to 50°C and stirred for 16 hours. The mixture was filtered and concentrated under reduced pressure to obtain compound 18-1. LCMS (ESI) m / z: 561.4 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 18-2 At 20°C, compound 18-1 (80mg, 142.69μmol) was dissolved in methanol (2mL) and sodium hydroxide solution (28.54mg sodium hydroxide dissolved in 1mL water) was added. Stirred at 20°C for 16 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25mm*4μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 32%~52%) to give the trifluoroacetate salt of compound 18-2. LCMS (ESI) m / z: 533.3 (M+1). Step 3: Preparation of the trifluoroacetate salt of compound 18 At 20°C, the trifluoroacetate salt of compound 18-2 (42mg, 78.86μmol) was dissolved in dichloromethane (1mL), trifluoroacetic acid (616.00mg, 5.40mmol) was slowly added, and the mixture was stirred at 20°C for 2 hours. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: 3_Phenomenex Luna C18, 70*30mm*3μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 5%~25%) to obtain the trifluoroacetate salt of compound 18. LCMS (ESI) m / z: 433.2 (M+1). 1 H NMR (400 MHz, CD3OD) δ ppm 1.02 - 1.15 (m, 2 H) 1.23 - 1.40 (m, 2 H) 1.42 - 1.54 (m, 2 H) 3.17 - 3.28 (m, 2 H) 3.51 (br dd, J=13.27, 8.25 Hz, 2 H) 3.70 - 4.07 (m, 2 H) 4.43 (td, J=7.27, 3.91 Hz, 1 H) 4.62 - 4.69 (m, 2 H) 5.01 (br s, 2 H) 7.20 (s, 1 H) 7.84 (br d, J=8.44 Hz, 1 H) 8.33 (br s, 1 H) 8.54 - 8.72 (m, 1 H) 9.07 (br d, J=5.99 Hz, 1 H).

[0144] JPEG2024541618000052.jpg84170 Step 1: Preparation of the trifluoroacetate salt of compound 19-1 At room temperature, trifluoroacetate salt of compound 7-7 (55 mg, 140.51 μmol) and N-(2-oxycarbonylethyl)carbamate t-butyl ester (22.37 mg, 140.51 μmol) were dissolved in dichloromethane (1 mL) and methanol (0.5 mL), and glacial acetic acid (16.88 mg, 281.03 μmol) was added and stirred at 50° C. for 3 hours. At 20° C., sodium cyanoborohydride (26.49 mg, 421.54 μmol) was added and stirred at 20° C. for 1 hour, and then heated to 50° C. and stirred for 16 hours. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by preparative HPLC (column: 3_Phenomenex Luna C18, 75×30 mm×3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid and acetonitrile; the proportion of acetonitrile in the mobile phase was 25%-45%) to give the trifluoroacetate salt of compound 19-1. LCMS (ESI) m / z: 535.3 (M+1). Step 2: Preparation of trifluoroacetic acid of compound 19-2 At room temperature, the trifluoroacetate salt of 19-1 (22 mg, 41.15 μmol) was dissolved in dichloromethane (1 mL), and trifluoroacetic acid (469.22 mg, 4.12 mmol) was added and stirred at 20° C. for 2 hours. The mixture was concentrated under reduced pressure to give the trifluoroacetate salt of compound 19-2. LCMS (ESI) m / z: 435.1 (M+1). Step 3: Preparation of the trifluoroacetate salt of compound 19 At room temperature, the trifluoroacetate salt of 19-2 (17.8 mg, 40.97 μmol) was dissolved in methanol (1 mL), and sodium hydroxide solution (8.19 mg dissolved in 0.5 mL of water) was added and stirred at 20° C. for 16 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: 3_Phenomenex Luna C18, 75×30 mm×3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 10% to 30%) to give the trifluoroacetate salt of compound 19. LCMS (ESI) m / z: 407.1 (M+1). 1 H NMR (400 MHz, CD3OD) δ ppm 0.90 - 1.01 (m, 2 H) 1.36 (br d, J=6.97 Hz, 2 H) 3.13 (t, J=5.69 Hz, 2 H) 3.64 (t, J=5.69 Hz, 2 H) 4.27 - 4.36 (m, 1 H) 4.44 (s, 2 H) 4.72 - 4.75 (m, 2 H) 6.69 (s, 1 H) 7.73 (d, J=8.44 Hz, 1 H) 8.37 (s, 1 H) 8.46 (d, J=8.44 Hz, 1 H) 8.94 (s, 1 H).

[0145] JPEG2024541618000053.jpg72170 Step 1: Preparation of compound 20-1 Compound 4-11 (15 mg, 29.91 μmol) was dissolved in methanol (2 mL) at room temperature, wet Pd / C (10 mg, 50% water content) was added, and the mixture was stirred at 10-15 °C under hydrogen (15 Psi) atmosphere for 2 h, filtered and concentrated under reduced pressure to give compound 20-1. LCMS (ESI) m / z: 504.2 (M+1). Step 2: Preparation of the hydrochloride salt of compound 20-2 Compound 20-1 (16 mg, 28.59 μmol) was dissolved in methanol (1 mL) and water (0.5 mL) at room temperature, sodium hydroxide (6.86 mg, 171.57 μmol) was added, and the mixture was stirred at 10 to 15° C. for 5 hours. The reaction solution was adjusted to pH=1 to 2 with 1M aqueous hydrochloric acid solution and concentrated to obtain the hydrochloride salt of compound 20-2. LCMS (ESI) m / z: 476.1 (M+1). Step 3: Preparation of the trifluoroacetate salt of compound 20 At room temperature, the hydrochloride salt of compound 20-2 (14 mg, 29.44 μmol) was dissolved in dichloromethane (1 mL), trifluoroacetic acid (0.5 mL) was added, and the mixture was stirred at 25-30° C. for 1 h. Concentration was performed, and the residue was purified by preparative HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 18%-38%) to obtain the trifluoroacetate salt of compound 20. LCMS (ESI) m / z: 376.0 (M+1). 1 H NMR (400 MHz, CDCl3) δ = 14.51 (s, 1H), 10.22 (s, 1H), 9.01 (s, 1H), 8.51 (s, 1H), 7.85 (s, 1H), 7.43 (m, 1H), 6.68 (s, 1H), 3.13 (s, 3H), 2.74 (s, 2H), 2.39 (s, 2H), 1.36 - 1.31 (m, 2H), 1.14 (s, 2H).

[0146] JPEG2024541618000054.jpg47170 Step 1: Preparation of compound 21 Compound 5-5 (105 mg, 258.35 μmol) was added to hydrobromic acid (12 mL, 40% aqueous solution) and stirred at 110° C. for 8 h. Concentrated, the residue was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100*25 mm*4 μm; mobile phase: 0.05% aqueous trifluoroacetic acid-acetonitrile; gradient: acetonitrile: 29% to 49%) to give compound 21. LCMS (ESI) m / z: 365.3 (M+1). 1H NMR (400 MHz, DMSO-d6) δ = 8.88 (s, 1H), 8.42-8.40 (m, 1H), 7.92 (s, 1H), 7.84-7.82 (m, 1H), 6.60 (s, 1H), 4.84 (s, 1H), 4.44 (s, 1H), 1.32 - 1.30 (m, 2H), 1.00 (s, 2H).

[0147] JPEG2024541618000055.jpg81170 Step 1: Preparation of compound 22-1 At room temperature, compound 7-7 (70.00 mg, 178.84 μmol) and (R)-(+)-2,2-dimethyl-1,3-dioxo-4-aldehyde pentane (46.55 mg, 357.67 μmol) were dissolved in anhydrous dichloromethane (4 mL) and anhydrous methanol (2 mL), then acetic acid (16.11 mg, 268.25 μmol) was added at 20-30 ° C, the reaction liquid was heated to 40 ° C and stirred for 1 hour, then the temperature was lowered to 20-30 ° C, pyridine borane (49.86 mg, 536.51 μmol) was added, the temperature was raised to 40 ° C and stirred for 16 hours, reacted and concentrated, 10 mL of dichloromethane was added, washed with saturated sodium bicarbonate (10 mL * 2) and brine (10 mL) in sequence, dried and concentrated to obtain compound 22-1. LCMS (ESI) m / z: 506.1 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 22 At room temperature, concentrated hydrochloric acid (0.5mL) was added to a solution of compound 22-1 (35.00mg, 69.23μmol) in ethanol (1.5mL) and water (1.0mL), and the reaction solution was stirred at 40℃ for 22 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product. The product was purified by preparative HPLC (column: YMC Triart C18 150*25mm*5μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution and acetonitrile; the ratio of acetonitrile in the mobile phase was 11% to 31%, 10min) to obtain the trifluoroacetate salt of compound 22.

[0148] JPEG2024541618000056.jpg87170 Step 1: Preparation of Compound 2-9 At room temperature, compound 2-9 (50 mg, 123.32 μmol) was dissolved in anhydrous N,N-dimethylformamide (3 mL), and the reaction solution was cooled to 0° C., and then sodium hydride (5.43 mg, 135.65 μmol) and difluoroethyl triflate (29.04 mg, 135.65 μmol) were added in sequence under nitrogen protection. The reaction solution was stirred at 25° C. for 1 hour. Compound 23-1 was obtained without post-treatment of the reaction solution. LCMS (ESI) m / z: 470.2 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 23 At room temperature, a solution of compound 23-1 (57 mg, 121.41 μmol) in anhydrous N,N-dimethylformamide (3 mL) was added to a solution of sodium hydroxide (4.86 mg, 121.41 μmol) in water (1 mL), and the reaction solution was stirred at 25 ° C. for 3 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product. The product was purified by preparative HPLC (column: YMC Triart C18 150 * 25 mm * 5 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution and acetonitrile; the ratio of acetonitrile in the mobile phase was 39% to 59%, 10 min) to obtain the trifluoroacetate salt of compound 23. LCMS (ESI) m / z: 442.1 (M + 1). 1 H NMR (400 MHz, DMSO-d6) δ ppm 14.83 - 15.13 (m, 1 H),8.85 - 8.94 (m, 1 H),8.54 - 8.62 (m, 1 H),8.41 - 8.48 (m, 1 H),7.88 - 7.99 (m, 1 H),6.99 - 7.07 (m, 1 H),6.06 - 6.48 (m, 1 H),4.65 - 4.74 (m, 2 H),4.52 - 4.56 (m, 2 H),4.45 - 4.50 (m, 1 H),4.05 - 4.18 (m, 2 H),3.13 - 3.24 (m, 3 H),1.28 - 1.38 (m, 2 H), 0.96 - 1.07 (m, 2 H).

[0149] JPEG2024541618000057.jpg48170 Step 1: Preparation of compound 24 At 0°C, sodium hydride (39.46 mg, 986.57 μmol) was added to a solution of compound 2-9 (0.10 g, 246.64.5 μmol) in DMF (4 mL), and after 10 minutes, compound 1-fluoro-2-iodoethane (85.81 mg, 493.28 μmol) was added to the reaction solution and stirred for 1 hour. The reaction solution was quenched with saturated ammonium chloride solution (10 mL), extracted with dichloromethane (10 mL * 2), washed with saturated saline (10 mL * 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: YMC Triart 30 * 150 mm * 7 μm; mobile phase: aqueous hydrochloric acid and acetonitrile; the ratio of acetonitrile in the mobile phase was 13% to 33%, 10 min) to obtain compound 24. LCMS (ESI) m / z: 404.2 (M + 1). 1H NMR (400 MHz, DMSO-d6) δ = 8.93 (s, 1H), 8.83 (s, 1H), 8.54 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 4.83 (br s, 2H), 4.80 - 4.72 (m, 2H), 4.60 (s, 2H), 4.51 - 4.44 (m, 1H), 4.09 - 4.01 (m, 2H), 3.20 - 3.18 (m, 3H), 1.32 (br d, J = 6.5 Hz, 2H), 1.04 (br s, 2H).

[0150] JPEG2024541618000058.jpg51170 Step 1: Preparation of compound 25 At 0°C, sodium hydride (1.58mg, 39.56μmol) was added to a solution of compound 22-1 (0.02g, 39.56mmol) in DMF (2mL), and after 10 minutes, compound methyl iodide (39.56μmol, 2.46μL) was added to the reaction solution and stirred for 1 hour. The reaction solution was quenched with saturated ammonium chloride solution (10mL), extracted with dichloromethane (10mL*2), washed with saturated saline (5mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: 0.05% ammonium bicarbonate aqueous solution and acetonitrile; the proportion of acetonitrile in the mobile phase was 29%~59%, 9min) to obtain compound 25. LCMS (ESI) m / z: 492.2(M+1). 1 H NMR (400 MHz, DMSO-d6) δ = 8.88 (s, 1H), 8.54 (s, 1H), 8.44 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 6.93 (s, 1H), 4.70 (br d, J = 1.5 Hz, 2H), 4.52 (s, 2H), 4.48 (br dd, J = 2.9, 5.8 Hz, 1H), 4.42 - 4.32 (m, 2H), 3.92 - 3.84 (m, 1H), 3.79 - 3.65 (m, 2H), 3.18 (s, 3H), 1.39 (s, 3H), 1.36 - 1.31 (m, 2H), 1.28 (s, 3H), 1.26 - 1.22 (m, 2H).

[0151] JPEG2024541618000059.jpg49170 Step 1: Preparation of compound 26 At room temperature, an aqueous solution (0.5 mL) of sodium hydroxide (15.82 mg, 395.60 μmol) was added to compound 22-1 (20.00 mg, 39.56 μmol) in methanol (1 mL) and stirred at 40 ° C for 16 hours. After filtration, the filtrate was purified by preparative HPLC (column Waters Xbridge 150 * 25 mm * 5 μm; mobile phase: 0.05% ammonium bicarbonate aqueous solution and acetonitrile; the ratio of acetonitrile in the mobile phase was 25% to 55%, 10 min) to obtain compound 26. LCMS (ESI) m / z: 478.3 (M + 1). 1 H NMR (400 MHz, CD3OD) δ ppm 8.83 (br s, 1 H),8.51 (br d, J=8.31 ​​Hz, 1 H),8.37 (m, 1 H),7.69 (m, 1 H),6.72 (s, 1 H),4.56 - 4.68 (m, 2 H),4.51 (s, 2 H),4.36 - 4.44 (m, 1 H),4.25 - 4.34 (m, 1 H),4.13 (dd, J=8.25, 6.30 Hz, 1 H),3.79 (dd, J=8.38, 6.30 Hz, 1 H),3.60 (dd, J=8.19, 5.62 Hz, 2 H),1.45 (s, 3 H),1.41 (br d, J=6.72 Hz, 2 H), 1.37 (s, 3 H), 1.01 (br s, 2 H).

[0152] JPEG2024541618000060.jpg73170 Step 1: Preparation of compound 27-1 Compound 7-7 (50 mg, 127.74 μmol) was dissolved in anhydrous dichloromethane (5 mL) at room temperature, and N,N-di(tert-butoxycarbonyl)thiourea (42.36 mg, 153.29 μmol), triethylamine (38.78 mg, 383.22 μmol) and copper chloride (20.61 mg, 153.29 μmol) were added in sequence, and the reaction solution was stirred at 20° C. for 12 hours. The reaction solution was filtered and concentrated under reduced pressure to give compound 27-1. LCMS (ESI) m / z: 634.3 (M+1). Step 2: Preparation of the trifluoroacetate salt of compound 27 At room temperature, compound 27-1 (80 mg, 126.24 μmol) was dissolved in ethanol (3 mL) and water (2 mL), and 12 M hydrochloric acid (12 M, 2 mL) was added to the reaction solution, and the reaction solution was stirred at 80 ° C for 1 hour. The reaction solution was concentrated under reduced pressure to obtain a crude product. The trifluoroacetate salt of compound 27 was obtained by purification using preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase: 0.05% trifluoroacetic acid aqueous solution and acetonitrile; the ratio of acetonitrile in the mobile phase was 18% to 48%, 9 min). LCMS (ESI) m / z: 406.2 (M + 1).

[0153] JPEG2024541618000061.jpg120170 Step 1: Preparation of compound 28-2 At 0°C, compound 28-1 (1g, 4.55mmol) was dissolved in DCM (10mL) and slowly added to sodium hydroxide (182.12mg, 4.55mmol) in water (10mL), and reacted at 0-25°C for 5 hours. After diluting the reaction solution with water (20mL), it was extracted with dichloromethane (60mL), and the organic layer was washed with saturated saline (30mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 28-2. LCMS (ESI) m / z: 184.1(M+1). Step 2: Preparation of compound 28-3 Compound 28-2 (19.50 mg, 106.45 μmol) and compound 7-7 (50 mg, 127.74 μmol) were dissolved in acetonitrile (1 mL), and then calcium triflate (15.00 mg, 40.67 μmol) was added, and the mixture was stirred at 45 °C for 16 h. The mixture was monitored and found that the raw materials were not completely reacted. The reaction solution was heated to 60 °C and the reaction was continued for 16 h. The reaction solution was filtered, and the filtrate was purified by preparative HPLC (column: YMC Triart C18 150 * 25 mm * 5 μm; mobile phase: [0.01% hydrochloric acid aqueous solution and acetonitrile; the proportion of acetonitrile in the mobile phase was 16% ~ 46%, 8.5 min) to obtain compound 28-3. LCMS (ESI) m / z: 575.3 (M + 1). Step 3: Preparation of the trifluoroacetate salt of compound 28 At room temperature, a solution of compound 28-3 (20 mg, 34.81 μmol) in anhydrous methanol (1 mL) was added with a solution of sodium hydroxide (6.96 mg, 174.04 μmol) in water (0.5 mL). The mixture was stirred at 25 °C for 2 h. The reaction solution was filtered, and the filtrate was purified by preparative HPLC (column: Phenomenex Synergi Polar-RP 100 * 25 mm * 4 μm; mobile phase [0.05% trifluoroacetic acid aqueous solution and acetonitrile; the proportion of acetonitrile in the mobile phase was 15% to 45%, 9 min) to obtain the trifluoroacetate salt of compound 28. LCMS (ESI) m / z: 547.3 (M+1).

[0154] JPEG2024541618000062.jpg81170 Step 1: Preparation of compound 29-2 At room temperature, compound 7-7 (50 mg, 127.74 μmol) and compound 29-1 (92.33 mg, 255.48 μmol) were dissolved in methanol (2 mL) and dichloromethane (4 mL), and then acetic acid (11.5 mg, 191.61 μmol) was added and stirred at 40° C. for 1 hour. The temperature was lowered to 10-20° C., pyridine borane (35.61 mg, 383.22 μmol) was added, and the mixture was stirred at 40° C. for 16 hours. The reaction solution was concentrated under reduced pressure to obtain compound 29-2. LCMS (ESI) m / z: 737.4 (M+1). Step 2: Preparation of the hydrochloride salt of compound 29 At room temperature, compound 29-2 (94 mg, 127.58 μmol) was dissolved in water (2 mL) and methanol (3 mL), concentrated hydrochloric acid (1.02 g, 10 mmol) was added, and the mixture was stirred at 50-55 ° C for 16 hours. The reaction solution was purified by preparative HPLC (column: YMC Triart C18 150 * 25 mm * 5 μm; mobile phase: 0.01% hydrochloric acid aqueous solution and acetonitrile; the ratio of acetonitrile in the mobile phase was 9% to 29%, 10 min) to obtain the hydrochloride salt of compound 29. LCMS (ESI) m / z: 509.2 (M + 1). Biological evaluation

[0155] Experimental example 1: Minimum bacteriostatic concentration (MIC) detection 1) Manufacturing of compound mother boards On the day of the experiment, the compound in the flask was dissolved in 100% DMSO so that the mother solution concentration was 0.4 mg / mL. If the mother solution is not used on the day, it is stored at -80°C. In a 96-well microplate (V-bottom), compound mother solutions and standard antibiotics were diluted 2-fold gradient with the corresponding solvents to obtain 100x working solutions (well 1 to well 7) sequentially. The concentrations of compounds were 400, 200, 100, 50, 25, 12.5, 6.25, and 3.125 μg / mL. 100% DMSO was used as the growth control (well 8). This is the compound mother plate. 2) Preparation of inoculum One day before the experiment, aerobic bacteria (Staphylococcus epidermidis) from a -80°C frozen tube was streaked onto an MHA (cation-adjusted Mueller-Hinton agar) plate. The plate was placed in an incubator at 35+ / -2°C and cultured aerobically for 18 to 24 hours. Two days before the experiment, anaerobic bacteria (Propionibacterium acnes) in a -80℃ freezing tube was streaked onto an MBA (Brucella Agar + 5% (v / v) defibrinated sheep blood + 5μg / mL Hemin + 1μg / mL Vitamine K1) plate, placed in an anaerobic incubator at 35+ / -2℃, and cultured for 42 to 48 hours. On the day of the experiment, the plate was removed, the clones on the plate were taken out and suspended in saline, and then the turbidity of the bacterial suspension was adjusted to OD600 = 0.2 using a turbidimeter. The bacterial suspension was 1.0-2.0 × 10 8 CFU / mL. The turbidity-adjusted bacterial suspension was then added to the test medium to measure ~5 × 10 5 CFU / mL, ~1 × 10 for anaerobic bacteria 6 Dilute to the appropriate concentration of CFU / mL. This is the inoculum. 3) Detection of minimum bacteriostatic concentration (MIC) 2 μl of 100× high concentration working solution, which was serially diluted 2-fold from the compound mother plate (prepared in step 1), was transferred to a round-bottom 96-well plate, and then 198 μL of bacterial inoculum (prepared in step 2) was added per well to obtain the MIC test plate. Thus, the final test concentrations of the compounds were 4, 2, 1, 0.5, 0.25, 0.125, 0.06, and 0.03 μg / mL. The total volume per well of the test plate was 200 μL, and the 1% DMSO, ~5×10 5 CFU / mL of aerobic bacteria, and ~1 × 10 6 Contains anaerobic bacteria in CFU / mL. All test plates for aerobic bacteria were incubated aerobically at 35+ / -2°C for 16-20 h, and all test plates for anaerobic bacteria were incubated in an anaerobic incubator at 35+ / -2°C for 48 h. NOTE: For anaerobic bacteria, the bacterial solution preparation in step 2 and the bacterial solution inoculation in step 3 are all performed in an anaerobic workstation. 4) Reading the minimum bacteriostatic concentration (MIC) After incubation, the test plates were visually inspected and the wells that completely or significantly inhibited the growth of the bacteria contained the lowest bacteriostatic drug concentration. 5) The experimental results are shown in Table 1. JPEG2024541618000063.jpg247170

[0156] Experimental Example 2: Pharmacokinetic evaluation of compounds 1) Experimental materials CD-1 mice (male, Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) 2) Experimental procedure The pharmacokinetic characteristics of the compounds in rodents after intravenous and oral administration were tested using the standard method. In the experiment, the candidate compounds were formulated into clear solutions and administered intravenously and orally once to mice. The solvent for intravenous and oral administration was a mixture of 10% DMSO + 90% (20% SBE-β-CD). Four male CD-1 mice were used in this project, two of which were administered intravenously at a dose of 1 mg / kg, and plasma samples were taken at 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h after administration. The other two mice were administered orally at a dose of 2 mg / kg, and plasma samples were taken at 0.25, 0.5, 1, 2, 4, 8, and 24 h after administration. After blood samples were collected, they were placed on ice and the plasma was centrifuged within 1 hour (centrifugation conditions: 6000g, 3 minutes, 2-8℃). Plasma samples were stored in a refrigerator at -80°C before analysis. Blood concentrations were quantitatively analyzed using LC-MS / MS analysis, and peak concentrations (C max ), clearance (CL), half-life (T 1 / 2 ), tissue distribution (Vdss), area under the drug time curve (AUC 0~last Pharmacokinetic parameters such as bioavailability (F) and drug availability (DHA) were calculated. 3) The experimental conclusions are shown in Table 4. JPEG2024541618000064.jpg51170 Experimental Conclusion: The compounds of the present invention have good pharmacokinetic properties, including good oral bioavailability and oral exposure.

[0157] Experimental Example 3: Study of the in vivo efficacy of compounds 1) Experimental materials Experimental strain: Propionibacterium acnes ATCC 6919 (Beijing Baiou Bowei Biotechnology Co., Ltd.) Experimental animal: Balb / C mouse (Zhejiang Wetong Lihua Experimental Animal Technology Co., Ltd.) 2) Experimental Method 1. Construction of Acne Model Balb / C mice were divided into groups, numbered, and adapted for one week. On the day of model creation, Propionibacterium acnes was taken, the OD600 was measured using a microplate reader, and diluted to OD600 = 1 in BHI medium (approximately 5 × 10 8CFU / mL), centrifugation was performed, the supernatant was discarded, and 1 × 10 8 After the model preparation started, the mouse was anesthetized using a small animal anesthesia machine, the gas volume and isoflurane volume of the anesthesia machine were adjusted, and the mouse was placed in an anesthesia induction box to induce anesthesia. When there were no obvious signs of activity, the mouse was taken out and the toe was pinched with tweezers or hemostatic forceps to test the toe pinch reaction. If there was no reaction such as retreating and pain, surgery was performed. The anesthetized mouse was fixed on a mouse board, and anesthesia was maintained by adjusting the gas volume or isoflurane volume (isoflurane anesthesia induction volume 3% to 4%, anesthesia maintenance volume 1% to 2%, air flow rate: 300 to 500 mL / min). Blank control group: 20 μL of PBS was injected into the left ear skin of each mouse. Model group, measurement target drug group: 20 μL of Propionibacterium acnes PBS suspension was injected into the left ear skin of each mouse. 4, 20, 28, and 44 hours after injection, Propionibacterium acnes was administered to the mice in each group according to the administration method and dosage listed in Table 5. At the end of the experiment, 48 hours after injection of Propionibacterium acnes, the ears of the mice in each group were photographed, the thickness of the left ear was measured with a vernier caliper, and the left ear was taken for tissue homogenization to detect the amount of bacteria carried in the ear and the levels of IL-6 and IL-8 (because mice do not express IL-8, the functional homolog CXCL1 / KC was detected). 2. Drug Preparation The drugs to be measured were Compound 6, Compound 7, and Compound 12, all of which were hydrochlorides. Compound 6, Compound 7, and Compound 12 that appeared in this experiment were all obtained by adding the corresponding hydrochloride drug solvent to 40% DMSO + 60% glycerin, adding the drug to DMSO and heating it to 100°C in a water bath, and then adding glycerin to obtain a bright yellow viscous solution. 3. The administration method and dosage are shown in Table 5 below. JPEG2024541618000065.jpg125170 Administration area: The ear to which Propionibacterium acnes is injected is the left ear. Administration times: 4, 20, 28, and 44 hours after Propionibacterium acnes injection, for a total of 4 doses. 4. How to create a model For the compound 6, compound 7, compound 12 and model groups, Balb / C mice were anesthetized using a small animal anesthesia machine and isoflurane, and then fixed to an anesthesia maintenance platform. Then, 1 × 10 8 CFU / mL Propionibacterium acnes PBS suspension was injected, and a blank control group was injected with an equal volume of 1x PBS. 5. Detection Indicators Gross photography: 48 hours after injection of Propionibacterium acnes, mouse ears were grossly photographed. Ear thickness measurement: 48 hours after injection of Propionibacterium acnes, the ear thickness of the mice was measured using a caliper. Detection of ear bacterial load: 48 hours after injection of Propionibacterium acnes, the left ear of the mouse was homogenized in 1 mL of PBS, and 200 μL of the homogenate was taken in three aliquots, each of which was diluted with 800 μL of PBS. 100 μL of the diluted homogenate was taken and diluted 10-fold, and the above procedure was repeated to perform a total of 5 gradient dilutions. The homogenate of each gradient was applied to BHI solid medium and cultured in an anaerobic environment at 37°C for 48 hours, after which the number of colonies was calculated. BCA protein detection in mice: 48 hours after injection of Propionibacterium acnes, the left ear of the mouse was homogenized in 1 mL of PBS using a BCA protein concentration measurement kit, and the dilution factor equivalent to a mass-volume ratio of 1:9 homogenate was calculated and centrifuged at 1500 g for 10 minutes. Each sample group was diluted 10 times with PBS. 20 μL of sample was taken and added to a 96-well plate. 200 μL of BCA working solution was added to each well and left at 37 °C for 15 to 30 minutes. A562 was measured with a microplate reader, a calibration curve was created, and the BCA concentration was calculated. This gave the levels of IL-6 and CXCL1. 3) The experimental conclusions are shown in Tables 6, 7, and 8. JPEG2024541618000066.jpg4417048 hours after injection of Propionibacterium acnes, the thickness of the ears of mice in each group was measured using a digital caliper. The results are shown as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001 compared with blank control group # p<0.05, ## p<0.01, ### p<0.001 compared with the model group. JPEG2024541618000067.jpg4417048 hours after injection of Propionibacterium acnes, the left ear tissue was collected and the amount of bacteria carried was detected. The results are shown as Mean ± SD. * p<0.05, ** p<0.01, *** p<0.001 compared with the model group. The left ear of the mice in the blank control group showed no change. The left ear of the mice in the acne model group showed obvious erythroderma. When the mice were treated with compound 6, compound 7 and compound 12, the erythroderma of the left ear of the mice was alleviated to a certain extent, and the situation was improved. As shown in Table 6, the thickness of the left ear of the mice in the acne model group was significantly increased compared with that of the mice in the blank control group (p<0.001). After topical treatment with compound 6, compound 7 and compound 12, the thickness of the left ear of the mice was significantly decreased (p<0.05), among which, the decrease in the thickness of the left ear of the mice after treatment with compound 7 was the most significant. As shown in Table 7, the bacterial load in the left ear of the mice was significantly reduced after treatment with compound 6, compound 7, and compound 12 (p<0.001). Among them, the bacterial load in the left ear of the mice was reduced the most after treatment with compound 7. JPEG2024541618000068.jpg4417048 hours after injection of Propionibacterium acnes, the thickness of the ears of mice in each group was measured using a digital caliper. The results are shown as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001 compared with blank control group# p<0.05, ## p<0.01, ### p<0.001 compared with the model group. From Table 8, compared with the blank control group, the contents of IL-6 and CXCL1 in the left ear tissue of the mice in the acne model group were significantly increased (p<0.001). When compound 6, compound 7, and compound 12 were applied and treated, the contents of IL-6 and CXCL1 in the left ear tissue of the mice were significantly decreased (p<0.001). Among them, compound 7 was the most effective after treatment. 4) Experimental conclusion This specification conducted animal experiments on the effects of various drugs on the symptoms of acne model mice, respectively established acne models and immunosuppressed mouse acne models, and proved that the test drugs improved the symptoms of acne model mice and reduced the levels of IL-6 and CXCL-1 in the lesion tissue. The main research results are as follows: Compound 6, Compound 7, and Compound 12 can all improve the thickness of the fungus-infected ears of acne model mice, reduce the symptoms of erythema, reduce the fungus burden in the fungus-infected ears of acne model mice, inhibit the growth of Propionibacterium acnes, and reduce the content of inflammatory factors IL-6 and CXCL1 in the fungus-infected ears of acne model mice.

Claims

1. A compound represented by formula (II), a stereoisomer or a pharma- ceutically acceptable salt thereof. T 1 , N, NH, CR 1 , and N + R 1 (A - ) are selected from T 2 N and CR 2 is selected from A - , F - , Cl - , B - , I - , O.H. - , and HCO 3 - is selected from X is -C(R 7 R 8 )- and -C(R 7 R 8 )-C(R 7 R 8 ) - is selected from Y is -O-, -S-, -NH-, or -C(R 7 R 8 ) - is selected from Z is -C(R 7 R 8 )--or -Y-Z- is -C(R 9 ) = C(R 9 ) - is selected from R 1 is H, F, Cl, Br, I, -OH, -NH 2 , and -CN and -CH 3 is selected from R 2 is H, F, Cl, Br, I, -OH, -NH 2 , -CN, and C 1~3 alkyl, wherein said C 1~3 Alkyl is optionally represented by 1, 2 or 3 R a is replaced by R 3 is H, F, Cl, Br, I, =O, -OH, -NH 2, -CN, -NHC(=NH)NH 2 , C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 alkoxy, wherein said C 1~3 Alkyl, C 1~3 Alkylamino, and C 1~3 Each alkoxy is independently selected from 1, 2 or 3 R b is replaced by Or, R 1 and R 3 together with the atom to which they are attached form a 5- to 6-membered heterocycloalkyl, a 5- to 6-membered heterocyclenyl, or a 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heterocycloalkyl, the 5- to 6-membered heterocyclenyl, and the 5- to 6-membered heteroaryl are each independently optionally selected from 1, 2, 3, or 4 R c is replaced by R 4 is H, C 1~3 Alkyl, C 3~6 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, 1~3 Alkyl, C 3~6 Cycloalkyl, phenyl, and 5- to 6-membered heteroaryl each independently optionally have 1, 2, 3, or 4 R d is replaced by R 5 is H, F, Cl, Br, I, -OH, -NH 2 -CN; R 6 is H, F, Cl, Br, I, -OH, -NH 2 -CN; Each R 7 , R 8 and R 9 are each independently H, F, Cl, Br, I, —OH, or —NH 2 -CN; Each R a are each independently F, Cl, Br, I, —OH, or —NH 2 -CN; Each R bare each independently F, Cl, Br, I, —OH, or —NH 2 , -C.N., C. 1~3 Alkoxy, C 3~6 cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and phenyl, wherein 1~3 Alkoxy, C 3~6 cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and phenyl are each independently optionally substituted by 1, 2, 3, or 4 R; Each R c are each independently F, Cl, Br, I, —OH, or —NH 2 , -CN, and -CH 3 is selected from Each R d are each independently F, Cl, Br, I, —OH, or —NH 2 -CN; Each R is independently F, Cl, Br, I, -OH, or -NH. 2 , -NO 2 , -CN, -ONHC(=NH)NH 2 , and C 1~3 alkyl, The "hetero" in the 5- to 6-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to 6-membered heterocyclenyl, and 5- to 6-membered heteroaryl each independently represents 1, 2, 3, or 4 heteroatoms or heteroatom groups selected from O, NH, S, and N.

2. Each R is independently -NO 2 , -ONHC(=NH)NH 2 , and -CH 3 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof according to claim 1, selected from:

3. Each R b are each independently F, Cl, Br, -OH, or -NH 2 , -OCH 2 CH 3, cyclobutyl, oxetanyl, oxolanyl, azetidinyl, 5-membered heteroaryl, and phenyl, wherein said —OCH 2 CH 3 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof of claim 1, wherein: cyclobutyl, oxetanyl, oxolanyl, azetidinyl, 5-membered heteroaryl, and phenyl are each independently optionally substituted with 1, 2, 3, or 4 R.

4.

5. Each R c are each independently -CH 3 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof according to claim 1, selected from:

6. Each R d are each independently F, Cl, Br, or -NH 2 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof according to claim 1, selected from:

7. R 1 is selected from H, or a pharma- ceutically acceptable salt thereof, according to claim 1.

8. R 2 is H and -CH 3 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof according to claim 1, selected from:

9. R 3 is H, F, Cl, Br, =O, -OH, -NH 2 , -CN, -NHC(=NH)NH 2 , -CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -N(CH 3 ) CH 2 CH 3 , and -OCH 3wherein said -NHC(=NH)NH 2 , -CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NHCH 2 CH 3 , -NHCH 2 CH 2 CH 3 , -N(CH 3 ) CH 2 CH 3 , and -OCH 3 each independently represents one, two or three R b 2. The compound, stereoisomer or pharma- ceutically acceptable salt thereof of claim 1, substituted with:

10.

11.

12. R 5 and R 6 is independently selected from H and F.

13. Each R 7 , R 8 and R 9 is independently selected from H. The compound, stereoisomer, or pharma- ceutically acceptable salt thereof of claim 1,

14.

15.

16. The compound according to claim 1, wherein the compound has a structure represented by formula (II-2): (However, X, Y, Z, T 1 , T 2 , R 3 , R 5 and R 6 is as defined in claim 1.

17. A compound represented by the following formula, a stereoisomer, or a pharma- ceutically acceptable salt thereof:

18. 18. The compound of claim 17, a stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the compound is a compound of the formula:

19. Use of a compound, stereoisomer or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 18 in the manufacture of an antibacterial and anti-inflammatory drug.

20. 20. The use according to claim 19, preferably in a medicament for treating acne.

Citation Information

Patent Citations

  • Novel carbostyrile compound, preparation and use

    CN101497612A

  • Antimicrobial fluoroquinolone analogs

    JP2011511811A

  • Antibacterial fluoroquinolone analogs

    WO2011031740A1

  • Antibacterial fluoroquinolone analogs

    WO2011031743A1

  • Antibacterial fluoroquinolone analogs

    WO2011031744A1